Note: Descriptions are shown in the official language in which they were submitted.
CA 02395717 2002-06-28
Description
Fused Imidazolium Derivatives
Technical Field
This invention relates to medicaments, particularly
novel fused imidazolium derivatives useful for the
treatment of cancers and novel synthetic intermediate
compounds thereof.
Background of the Invention
As imidazolium derivatives fused with aryl or
heteroaryl ring and having anti-tumor activity, only the
4,9-dioxonaphtho[2,3-d]imidazolium compounds (KP-1, KP-3
and the like) of the following formula have so far been
disclosed in Rhim. Pharm. Zh., 32(6), 10 - 11 (1998).
0 Me 0 it
+
~CI ~ ~ I N~Me
N CI- ~ CI-
0 Me 0 Et (KP-3)
(In the formula, Et and Me respectively represent ethyl and
methyl, the same shall apply hereinafter.)
J. Med. Chem., 7(3), 362 - 364 (1964) discloses a
compound having an antimicrobial action in which R' and R2
are both lower alkyl, or one is -lower alkylene- (an aryl
which may have one or more substituents) and the other is -
CH3, -(CH2) 3CH3 or -phenyl group, or one is -lower alkylene-
CO- (an aryl which may have one or more substituents) and
1
CA 02395717 2002-06-28
the other is -(CH2) 2CH (CH3) 2 or -(CH2) 3CH3r but there is no
disclosure on its anti-tumor activity.
Also, 4,9-dioxonaphtho[2,3-d]imidazolium derivatives
in which R1 and R2 of the general formula (I) of the
present invention, which will be described later, are both
lower alkyl groups are disclosed in J. Org. Chem. USSR, 1,
1479 - 85 (1965), JP-A-3-258765 and JP-A-6-59371 and the
like. However, there is no disclosure on the medicinal use
of these compounds.
British Patent No. 1314881 discloses 1,4-dihydro-1,4-
dioxonaphthalene derivatives useful as a herbicide, and JP-
B-54-25085 discloses isoquinoline-5,8-dione derivatives
useful as a herbicide, respectively. Also, several 1,4-
dihydro-1,4-dioxonaphthalene derivatives are commonly known
by Zh. Org. IQiim., 22(8), 1736 - 42 (1986), J. Gen. Chem.
USSR, 36, 649 - 652 (1966) and reagent catalogs [Sigma
Aldrich Library of Rare Chemicals Structure Index, with
update (Aldrich Chemical Company, Inc.) and the like].
However, all of these documents do not disclose on the
medicinal use of these compounds.
Imidazole derivatives fused with aryl ring are
disclosed in WO 97/30022, J. Med. Chem., 39, 1447 - 1451
(1996) and J. Med. Chem. , 7(3) , 362 - 364 (1964)
2
CA 02395717 2002-06-28
Disclosure of the Invention
Creation of an anticancer agent which exhibits
excellent anti-tumor activity and also has low toxicity is
still in great demand.
The present inventors have conducted intensive
studies on anticancer agents having less side effects and
found as a result of the efforts that novel imidazolium
derivatives fused with an aryl or heteroaryl ring,
characterized by being substituted at the 1- andJor 3-
position with substituted alkyl group etc., exhibit
excellent anti-tumor activity and low toxicity, thus they
can be useful as anticancer agents having wide margins of
safety. In addition, by finding a 2-acylamino-3-amino-1,4-
quinone derivative and a fused imidazole derivative useful
as their synthetic intermediates and further finding that
this synthetic intermediate 2-acylamino-3-amino-1,4-quinone
derivative itself also shows low toxicity and excellent
anti-tumor activity, the invention has been accomplished.
That is, the invention relates to a fused imidazolium
derivative represented by the following general formula (I)
and a pharmaceutical composition, particularly an
anticancer agent, which comprises this fused imidazolium
derivative and a pharmaceutically acceptable carrier.
3
CA 02395717 2002-06-28
0 R
i
A + (tR3 (I)
N2 X
0 R
(Symbols in the formula have the following meanings;
R1 and R2: the same or different from each other and
each represents -(lower alkyl having one or more
substituents selected from group B), -(lower alkenyl having
one or more substituents selected from group B), -(lower
alkynyl having one or more substituents selected from group
B), -RinD, -lower alkyl, -lower alkenyl or -lower alkynyl,
with the proviso that at least one of R' and R2 is -(lower
alkyl having one or more substituents selected from group
B), -(lower alkenyl having one or more substituents
selected from group B), -(lower alkynyl having one or more
substituents selected from group B), -(cycloalkyl having
one or more substituents) or -(five- to seven-membered
saturated heterocyclic ring which may have one or more
substituents),
group B: -ORa, -SR8, -prodrug-formed OH, -0-lower
alkylene-ORa, -0-lower alkylene-O-lower alkylene-ORa,
-0-lower alkylene-NR$R'', -0-lower alkylene-O-lower
alkylene-NRaRb, -0-lower alkylene-NR -lower alkylene-NRaR'',
-OCO-NRaRb, -SORa, -SO2Ra, -SO2NRaRb, -NR$-SO2Rb, -CO2H,
-NRaRb, -NR -lower alkylene-NRaRb, -N (-lower alkylene-
NRaRb)2r -RinD, -NO2, -CN, -halogen, -CO2Ra, -COO-, -CONR$Rb,
-CONRa-O-Rb, -NRa-CORb, -NRa-CO-NRbR , -OCORa and -CO-Ra,
4
CA 02395717 2002-06-28
Ra, Rb and R : the same or different from one another
and each represents -H, -lower alkyl, -lower alkylene-RinD
or -RinD,
RinD: -(five- to seven-membered saturated
heterocyclic ring which may have one or more substituents),
-(cycloalkyl which may have one or more substituents),
-(cycloalkenyl which may have one or more substituents),
-(aryl which may have one or more substituents) or
-(heteroaryl which may have one or more substituents),
R3: -H or -(lower alkyl which may have one or more
substituents), or R2 and R3 may together form a lower
alkylene having from 2 to 5 carbon atoms which may be
interrupted with 0, S or NR 4 (R : -H or -lower alkyl),
ring A: aryl ring which may have one or more
substituents or heteroaryl ring which may have one or more
substituents, and
X-: counter anion, with the proviso that X does not
exist when the substituent -COO of the group B forms
intramolecular salt with imidazolium cation,
with the proviso that compounds having the following
combinations of R' and R2 are excluded:
(1) one is -lower alkylene-(aryl which may have one
or more substituents) and the other is -CH3,
- ( CH2 ) 3CH3 or -phenyl,
(2) one is -lower alkylene-CO-(aryl which may have
one or more substituents) and the other is
-(CH2) 2CH (CH3) 2 or - (CH2) 3CH3, or
5
---- - --------
CA 02395717 2002-06-28
(3) R' and R2 are both -benzyl,-( CHZ ) 20C2H5 or
-(CH2)20-COCH3; the same shall apply hereinafter.)
Also, the invention relates to a 2-acylamino-3-amino-
1,4-quinone derivative represented by the following general
formula (II) or a salt thereof, which is a synthetic
intermediate of the above general formula (I) and has
excellent anti-tumor activity by itself too, and to a
pharmaceutical composition, particularly an anticancer
agent, which contains this compound or a salt thereof and a
pharmaceutically acceptable carrier.
0
H
EA N'R
~ ( (II)
N'R2
0 0 R 3
(Symbols in the formula have the following meanings;
R'i and R2: the same or different from each other and
each represents -(lower alkyl having one or more
substituents selected from group B), -(lower alkenyl having
one or more substituents selected from group B), -(lower
alkynyl having one or more substituents selected from group
B), -RinD, -lower alkyl, -lower alkenyl or -lower alkynyl,
with the proviso that at least one of R1 and R2 is -(lower
alkyl having one or more substituents selected from group
B), -(lower alkenyl having one or more substituents
selected from group B), -(lower alkynyl having one or more
substituents selected from group B), -(cycloalkyl having
one or more substituents) or -(five- to seven-membered
6
CA 02395717 2002-06-28
saturated heterocyclic ring which may have one or more
substituents),
group B: -ORa, -SRa, -prodrug-formed OH, -0-lower
alkylene-ORa, -0-lower alkylene-0-lower alkylene-ORa,
-0-lower alkylene-NRaRb, -0-lower alkylene-O-lower
alkylene-NR8Rb, -0-lower alkylene-NR -lower alkylene-NRaR'',
-OCO-NRaRb, -SORa, -SO2Ra, -SO2NRaRb, -NRa-SO2Rb, -COZH,
-NR8Rb, -NR'-lower alkylene-NRaRb, -N(-lower alkylene-
NRaRb) 2r -RinD, -NO2, -CN, -halogen, -CO2Ra, -CONR$Rb,
-CONRa-O-Rb, -NRa-CORb, -NRa-CO-NRbRc, -OCORa and -CO-Ra,
Ra, Rb and R : the same or different from one another
and each represents -H, -lower alkyl, -lower alkylene-RinD
or -RinD,
RinD: -(five- to seven-membered saturated
heterocyclic ring which may have one or more substituents),
-(cycloalkyl which may have one or more substituents),
-(cycloalkenyl which may have one or more substituents),
-(aryl which may have one or more substituents) or
-(heteroaryl which may have one or more substituents),
R3: -H or -(lower alkyl which may have one or more
substituents), or R2 and R3 may together form a lower
alkylene having from 2 to 5 carbon atoms which may be
interrupted with 0, S or NR4 (R4: -H or -lower alkyl), and
ring A: aryl ring which may have one or more
substituents or heteroaryl ring which may have one or more
substituents,
with the proviso that compounds of the following table are
excluded;
7
- -- - ----------
CA 02395717 2007-07-31
CA 02395717 2002-06-28
Table 2
0
R ~? N~R~
~ ~ I
N'R' (II-E)
0 0 R3
Cam Z R -R1 -R2 -R3
E-1 CH H -Me -CH2-(3,4-Cl-Ph) 1VIe
E-2 CH H -CH(1VIe)2 -CH2z-(3,4-Cl-Ph) -Me
E-3 CH H -CH2-Ph -(4-MeO-Pb) -Me
E-4 CH H -CH2-Ph -(3-BrPh) -Me
E-5 CH H -CH2-Ph -CH2-(4-F-Ph) -Me
E-6 CH H -(ClQ2-Ph -CH2-(4-F-Ph) -Me
E-7 CH H -(CW2-OH -Me -Me
E-8 CH H -(CH9)2-OH CH,z-Ph -Me
E-9 CH H 4CHI)2-OH -(4-MeO-Pb) -Me
E-10 CH H -(CHQ2-OH -(4-MeCO-Pb) -Me
E-11 CH H -(CH,O2-OH -(3-BrPh) -Me
E-12 CH H -(CW2-Cl -CH2CO2Et -Me
E-13 CH H -CHaVIe)-COzH -Me -Me
E-14 CH H -CH(Me)-CONHMe -Me -Me
E-15 CH H -CH(Me)-CONHMe -CHaVIe)2 -Me
E-16 CH H -CH(Me)-CONHMe ~ -Me
E-17 CH H -CH(XVie)-CONHMe -Me -(CH~2Me
E-18 CH H -CHCMe)-CONHMe -Me -CH(Me)2
E-19 CH H -CHaVIe)-CONHOMe -Me -Me
E-20 N H -CH(Me)-CONHMe -Me -Me
E-21 N Me -CHMe)-CONHMe -Me -Me
E-22 CH H ~~8 -Me -Me
NH
Me
Me
(in this table, Comp means compound number, Me means methyl
group, Et means ethyl group and Ph means phenyl group, and
in the case of a substituted phenyl group, the substituent
is shown before Ph together with the substituting position,
8
CA 02395717 2002-06-28
e.g., 3,4-Cl-Ph represents 3,4-dichlorophenyl, the same
shall apply hereinafter).
The compounds shown in Table 2 are commonly known by
British Patent No. 1314881 and JP-B-54-25085 in relation to
herbicides, Zh. Org. Khim., 22(8), 1736 - 42 (1986) and J.
Gen. Chem. USSR, 36, 649 - 652 (1966) in relation to their
synthesis methods, and by reagent catalogs [Sigma Aldrich
Library of Rare Chemicals Structure Index, with update
(Aldrich Chemical Company, Inc.) and the like].)
In addition, the invention relates to a fused
imidazole derivative represented by the following general
formula (III) or a salt thereof, which is a novel synthetic
intermediate of the aforementioned general formula (I).
0 R1
~
N
A /> R3 (III)
N
0
(Symbols in the formula have the following meanings;
R1: -(lower alkyl having one or more substituents
selected from group B), -(lower alkenyl having one or more
substituents selected from group B), -(lower alkynyl having
one or more substituents selected from group B) or
-(cycloalkyl having one or more substituents), with the
proviso that a lower alkyl group having one or more
substituents selected from the group consisting of -NH2,
9
CA 02395717 2002-06-28
-NMe2, -NEt2, -OH, -halogen and -(phenyl which may be
substituted by -Cl, -F, -Me or -OMe) is excluded,
group B: -ORa, -SRa, -prodrug-formed OH, -0-lower
alkylene-OR$, -0-lower alkylene-0-lower alkylene-ORa,
-0-lower alkylene-NRaRb, -0-lower alkylene-O-lower
alkylene-NRaR'', -0-lower alkylene-NR -lower alkylene-NRaRb,
-OCO-NRaRb, -SORs, -SO2Ra, -SO2NRaRb, -NR$-SO2Rb, -CO2H,
-NRaRb, -NR -lower alkylene-NR$Rb, -N (-lower alkylene-
NRaRb) 2r -RinD, -NO2, -CN, -halogen, -CO2Ra, -CONRaRb,
-CONRa-O-Rb, -NRa-CORb, -NR4-CO-NRR , -OCOR$ and -CO-Ra,
Ra, Rb and R : the same or different from one another
and each represents -H, -lower alkyl, -lower alkylene-RinD
or -RinD,
RinD: -(five- to seven-membered saturated
heterocyclic ring which may have one or more substituents),
-(cycloalkyl which may have one or more substituents),
-(cycloalkenyl which may have one or more substituents),
-(aryl which may have one or more substituents) or
-(heteroaryl which may have one or more substituents),
R3: -H or -(lower alkyl which may have one or more
substituents), and
ring A: aryl ring which may have one or more
substituents or heteroaryl ring which may have one or more
substituents, the same shall apply hereinafter.)
The compounds of general formula (I), (II) and (III)
are further described.
CA 02395717 2002-06-28
According to this description, the term "lower" means
a straight or branched form of hydrocarbon chain having
from 1 to 6 carbon atoms. As the "lower alkyl", it is
preferably an alkyl group having from 1 to 4 carbon atoms,
and its particularly preferred examples include methyl,
ethyl, n-propyl, isopropyl, n-butyl and isobutyl groups.
As the "lower alkenyl", its preferred examples include
vinyl, allyl, 1-propenyl, isopropenyl, 1-butenyl, 2-butenyl
and 3-butenyl groups. As the "lower alkynyl", its
preferred examples include ethynyl, 1-propynyl, 2-propynyl,
1-butynyl, 2- butynyl, 3-butynyl and 1-methyl-2-propynyl
groups. Also, as the "lower alkylene", its preferred
examples include methylene, ethylene, trimethylene and 2,2-
dimethyltrimethylene groups.
The "aryl" means an aromatic hydrocarbon ring group,
and its preferred examples include aryl groups having from
6 to 14 carbon atoms, more preferably phenyl, naphthyl and
fluorenyl groups. Also, as the "aryl ring" in the ring A,
it is a ring which forms the above aryl ring, and its
preferred examples include benzene and naphthalene rings.
Examples of the "heteroaryl" include five- or six-
membered monocyclic heteroaryl groups containing from 1 to
4 hetero atoms selected from N, S and 0 and bicyclic
heteroaryl groups in which they are fused with a benzene
ring or five- or six-membered monocyclic heteroaryl ring,
which may be partially saturated. Also, when it contains N
atom, it may form N-oxide. In this case, furyl, thienyl,
11
CA 02395717 2002-06-28
pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl,
oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl,
tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl
and triazinyl groups are preferred as the five- or six-
membered monocyclic heteroaryl, and benzofuranyl,
benzothienyl, benzothiadiazolyl, benzothiazolyl,
benzoxazolyl, benzoxadiazolyl, benzoimidazolyl, indolyl,
isoindolyl, indazolyl, quinolyl, isoquinolyl, cinnolinyl,
quinazolinyl, quinoxalinyl, benzodioxolyl, indolizinyl and
imidazopyridyl groups are preferred as the bicyclic
heteroaryl. As the partially saturated heteroaryl,
1,2,3,4-tetrahydroquinolyl group and the like can be
exemplified. Further preferred are furyl, thienyl,
imidazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridadinyl,
indolyl, benzoimidazolyl, benzodioxonyl and quinolyl
groups, and particularly preferred are pyridyl, pyrazinyl
and pyrimidinyl groups.
The heteroaryl ring of the ring A is a ring which
forms the above heteroaryl group, preferably a five- or
six-membered monocyclic heteroaryl ring, and more preferred
are thiophene, furan, pyrrole, imidazole, oxazole,
thiazole, pyridine, pyrazine and pyrimidine rings.
As the "cycloalkyl", preferred are cycloalkyl groups
having from 3 to 10 carbon atoms and particularly preferred
are cyclopropyl, cyclopentyl, cyclohexyl and adamantyl
groups. As the "cycloalkenyl", preferred are cycloalkenyl
12
CA 02395717 2002-06-28
groups having from 3 to 8 carbon atoms and particularly
preferred are cyclopentenyl and cyclohexenyl groups.
As the "counter anion", there is no particular
limitation with the proviso that it is a pharmaceutically
acceptable anion as a counter anion of imidazolium cation,
and its preferred examples include monovalent or divalent
anions such as halogen ions, organic sulfonate ions
(methanesulfonate ion, ethanesulfonate ion,
benzenesulfonate ion, toluenesulfonate ion and the like),
acetate ion, trifluoroacetate ion, carbonate ion, sulfate
ion and the like, of which halogen ions are particularly
preferred.
As the "halogen", F, Cl, Br and I atoms can be
exemplified, and the "halogen ion" means their ions. The
"halogeno lower alkyl" is the aforementioned lower alkyl
which is substituted by one or more of the halogen, and is
preferably -CF3.
The "five- to seven-membered saturated heterocyclic
ring" is a five- to seven-membered monocyclic saturated
heterocyclic ring containing from 1 to 4 hetero atoms
selected from N, S and 0, or its cross-linked ring.
Preferred are tetrahydropyranyl, tetrahydrofuranyl,
pyrrolidinyl, piperazinyl, azepanyl, diazepanyl,
quinuclidinyl, piperidyl and morpholinyl groups.
The "-prodrug-formed OH" is a group which formed a
reversible prodrug derivative that can be restored to its
parent compound (original hydroxy compound) in the living
13
CA 02395717 2002-06-28
body, and its examples include groups described, e.g., in
Prog. Med., 5: 2157 - 2161 (1985). Its preferred examples
include -OCO-(lower alkylene which may have one or more
substituents)-COOR (R represents H or lower alkyl, the same
shall apply hereinafter), -OCO-(lower alkenylene which may
have one or more substituents)-COOR, -OCO-(aryl which may
have one or more substituents), -OCO-lower alkylene-O-lower
alkylene-COOR, -OCO-CO-R, -OCO-(lower alkyl which may have
one or more substituents), -OS02-(lower alkylene which may
have one or more substituents)-COOR, -O-phthalidyl, 5-
methyl-1,3-dioxolen-2-one-4-yl-methyloxy and the like.
As the substituent in the -(five- to seven-membered
saturated heterocyclic ring which may have one or more
substituents), -(cycloalkyl which may have one or more
substituents), -(cycloalkyl which has one or more
substituents), -(cycloalkenyl which may have one or more
substituents), -(aryl which may have one or more
substituents) or -(heteroaryl which may have one or more
substituents), it is not particularly limited but is
preferably from 1 to 4 substituents selected from the
following group C.
Group C: -lower alkyl, -halogen, -halogeno lower
alkyl, -ORa, -0-lower alkylene-OR$, -SR$, -NRaRb, -NO2r -CN,
-CO2Ra, -CO-NRaRb, -CORa, -NRa-CORb, -SO2NRaRb, -lower
alkylene-NRaRb, -aryl, -lower alkylene-aryl and -OCO-Ra (in
these formulae, Ra and Rb are as defined in the foregoing)
Among the group C, more preferred are -lower alkyl,
14
CA 02395717 2002-06-28
-halogen, -halogeno lower alkyl, -OH, -0-lower alkyl,
-0-lower alkylene-OH, -0-lower alkylene-O-lower alkyl,
-lower alkylene-NH2, -NH2, -NH-lower alkyl, -N(lower
alkyl) 2, -CO2H, -C02-lower alkyl, -CO-NH2, -S02-NH2, -NO2 and
-CN. The same shall apply hereinafter.
As the substituent of the "aryl ring which may have
one or more substituents" or "heteroaryl ring which may
have one or more substituents" in the ring A, the
aforementioned groups of the group C can be cited as
preferred examples, and more preferred groups are also the
same as described above. Particularly preferred'is -NO2.
Though the substituent the "lower alkyl which may
have one or more substituents" of R3 is not particularly
limited, it is preferably a substituent of the
aforementioned group B, more preferably -halogen,
-ORa, -SRa, -NRaRb, -NO2 or -CN .
In this connection, as the groups shown using Ra, Rb
and Rc in the aforementioned group B and group C, groups in
which Ra, Rb and R are -H or -lower alkyl are more
desirable.
The term "R2 and R3 together form a lower alkylene
having from 2 to 5 carbon atoms which may be interrupted
with 0, S or NR4 (R : -H or -lower alkyl)" means that R2 and
R3 together form a lower alkylene chain which may be
interrupted with 0, S or NR4 (preferably -(CH2)4-, -
(CH2) 20CH2- or -(CH2) 2N (Me) CH2-) , and combined with the
CA 02395717 2002-06-28
adjacent N and C atoms to form a five- to eight-membered
hetero ring which is fused with imidazole ring.
Preferred compound of the compound (I) or (II) of the
invention is,
(1) a compound in which at least one of R1 and R2 is
-(lower alkyl having one or more substituents selected from
the group B), -(lower alkenyl having one or more
substituents selected from the group B), -(lower alkynyl
having one or more substituents selected from the group B),
-(cycloalkyl having one or more substituents selected from
the group C) or -(five- to seven-membered saturated
heterocyclic ring which may have one or more substituents
selected from the group C); RinD is -(five- to seven-
membered saturated heterocyclic ring which may have one or
more substituents selected from the group C), -(cycloalkyl
which may have one or more substituents selected from the
group C), -(cycloalkenyl which may have one or more
substituents selected from the group C), -(aryl which may
have one or more substituents selected from the group C) or
-(heteroaryl which may have one or more substituents
selected from the group C); R3 is -H or -(lower alkyl which
may have one or more substituents selected from the group
B), or R2 and R3 may together form a lower alkylene having
from 2 to 5 carbon atoms which may be interrupted with 0, S
or NR4 (R4: -H or -lower alkyl); and ring A is aryl ring
which may have one or more substituents selected from the
16
CA 02395717 2002-06-28
group C or heteroaryl ring which may have one or more
substituents selected from the group C,
(2) a compound in which at least one of Ri and R2 is a
lower alkyl having one or more substituents selected from
the group B,
(3) a compound in which both of R1 and R2 are the same or
different lower alkyl having one or more substituents
selected from the group B,
(4) a compound in which at least one of Rl and R 2 is a
lower alkyl having one or more substituents selected from
the group consisting of -ORa, -NR$Rb, -NRa-CORb, -0-lower
alkylene-ORa, -0-lower alkylene-O-lower alkylene-ORa, -SRa,
-CONRaRb, -CN, -(cycloalkyl which may have one or more
substituents selected from the group C), -(five- to seven-
membered saturated heterocyclic ring which may have one or
more substituents selected from the group C), -(aryl which
may have one or more substituents selected from the group
C) and -(heteroaryl which may have one or more substituents
selected from the group C),
(5) a compound in which at least one of R1 and R2 is a
lower alkyl having one or more substituents selected from
the group consisting of -OR$, -0-lower alkylene-ORa,
-0-lower alkylene-O-lower alkylene-ORa, -(five- to seven-
membered saturated heterocyclic ring which may have one or
more substituents selected from the group C),
17
CA 02395717 2002-06-28
-(aryl which may have one or more substituents selected
from the group C) and -(heteroaryl which may have one or
more substituents selected from the group C),
(6) a compound in which at least one of Rl and R2 is a
lower alkyl substituted by a heteroaryl group selected from
furyl, thienyl, imidazolyl, pyridyl, pyrazinyl,
pyrimidinyl, pyridazinyl, indolyl, benzoimidazolyl,
benzodioxonyl and quinolyl group, which may have one or
more substituents selected from the group C,
(7) a compound in which one of R' and R2 is a lower alkyl
substituted by -0-lower alkyl and the other is a lower
alkyl substituted by one substituent selected from the
group consisting of -0-lower alkylene-O-lower alkyl,
-0-lower alkylene-O-lower alkylene-O-lower alkyl, -(aryl
which may have one or more substituents selected from the
group C), -(heteroaryl which may have one or more
substituents selected from the group C) and -0-lower alkyl,
(8) a compound in which at least one of R1 and R2 is a
lower alkyl having one substituent selected from the group
consisting of -(heteroaryl selected from pyridyl, pyrazinyl
and pyrimidinyl, which may have one or more substituents
selected from the group C), -0-lower alkylene-O-lower alkyl
and -0-lower alkyl,
(9) a compound in which R3 is methyl group,
(10) a compound in which the ring A is benzene ring which
may have one or more substituents selected from the group C
or a heteroaryl ring selected from thiophene, furan,
18
CA 02395717 2002-06-28
pyrrole, imidazole, oxazole, thiazole, pyridine, pyrazine,
pyridazine and pyrimidine ring, which may have one or more
substituents selected from the group C,
(11) a compound in which the ring A is benzene ring which
may be substituted by -NO2, or
(12) a compound in which X is a halogen ion.
Also, another preferred compound of the compound (I)
of the invention is a fused imidazolium derivative in which
R' and R2 are the same or different from each other and
each represents -(lower alkyl having one or more
substituents selected from group B'), -(lower alkenyl
having one or more substituents selected from group B'),
-(lower alkynyl having one or more substituents selected
from group B'), -(cycloalkyl which may have one or more
substituents selected from group C'), -(five- or six-
membered monocyclic heteroaryl which may have one or more
substituents selected from group C'), -(aryl which may have
one or more substituents selected from group C'), -(five-
to seven-membered saturated heterocyclic ring which may
have one or more substituents selected from group C'),
-lower alkylene-(aryl which may have one or more
substituents selected from group C'), -lower alkylene-CO-
(aryl which may have one or more substituents selected from
group C'), -lower alkyl, -lower alkenyl or -lower alkynyl,
with the proviso that at least one of R' and R2 is -(lower
alkyl having one or more substituents selected from group
B'), -(lower alkenyl having one or more substituents
19
CA 02395717 2002-06-28
selected from group B') or -(lower alkynyl having one or
more substituents selected from group B'); group B' is
-ORa, -SRa, -prodrug-formed OH, -0-lower alkylene-RinD, -
SORa, -SO2Ra, -SO2NRaRb, -NRa-SO2Rb, -CO2H, -NRaRb, -NR -lower
alkylene-RinD, -N(-lower alkylene-RinD)2, -NR -lower
alkylene-NRaRb, -N(lower alkylene-NRaRb) 2r -(five- to seven-
membered saturated heterocyclic ring which may have one or
more substituents selected from group C'), -(five- or six-
membered monocyclic heteroaryl which may have one or more
substituents selected from group C'), -cycloalkyl, -S-lower
alkylene-RinD, -NO2, -CN, -CO2Ra, -CONR$Rb, -NRa-CORb, -
OCORa, -CO-lower alkyl and -CO-(five- or six-membered
monocyclic heteroaryl which may have one or more
substituents selected from group C' ); Ra, Rb and Rc are the
same or different from one another and each represents -H,
-lower alkyl or -RinD; RinD is -(five- to seven-membered
-saturated heterocyclic ring which may have one or more
substituents selected from group C'), -(aryl which may have
one or more substituents selected from group C') or -(five-
or 6-membered monocyclic heteroaryl which may have one or
more substituents selected from group C'); group C' is
-lower alkyl, -halogen, -OR$, _SRa, -NRaRb, -NO2r -CN,
-CO2Ra, -CO-NR$Rb, -CORa, -NRa-CORb, and -OCO-Ra; R3 is -H or
-lower alkyl; ring A is benzene ring which may have a
substituent selected from the group consisting of -lower
alkyl, -ORa, -NRaRb, -CN, -halogen and -NO2; and X is
counter anion.
CA 02395717 2002-06-28
Among compounds (I) of the invention, particularly
preferred compounds are 1-[(6-chloro-3-pyridyl)methyl]-3-
(2-methoxyethyl)-2-methyl-4,9-dioxo-4,9-dihydro-lH-
naphtho[2,3-d]imidazol-3-ium, 1,2-dimethyl-4,9-dioxo-3-[(2-
tetrahydrofuranyl)methyl]-4,9-dihydro-lH-naphtho[2,3-
d]imidazol-3-ium, 1,3-bis(2-methoxyethyl)-2-methyl-4,9-
dioxo-4,9-dihydro-lH-naphtho[2,3-d]imidazol-3-ium, 3-(2-
methoxyethyl)-2-methyl-4,9-dioxo-l-(2-pyrazinylmethyl)-4,9-
dihydro-lH-naphtho[2,3-d]imidazol-3-ium, 1-[3-(1H-4-
imidazolyl)propyl]-3-(2-methoxyethyl)-2-methyl-4,9-dioxo-
4,9-dihydro-lH-naphtho[2,3-d]imidazol-3-ium, 3-(2-
methoxyethyl)-2-methyl-l-[(5-methyl-2-pyrazinyl)methyl]-
4,9-dioxo-4,9-dihydro-lH-naphtho[2,3-d]imidazol-3-ium, 2-
methyl-4,9-dioxo-l,3-bis(2-pyrazinylmethyl)-4,9-dihydro-lH-
naphtho[2,3-d]imidazol-3-ium, 1-[2-(2-methoxyethoxy)ethyl]-
3-(2-methoxyethyl)-2-methyl-4,9-dioxo-4,9-dihydro-lH-
naphtho[2,3-d]imidazol-3-ium, 1-{2-[2-(2-
methoxyethoxy)ethoxy]ethyl}-3-(2-methoxyethyl)-2-methyl-
4,9-dioxo-4,9-dihydro-lH-naphtho[2,3-d]imidazol-3-ium, 1-
(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(3-pyridylmethyl)-
4,9-dihydro-lH-naphtho[2,3-d]imidazol- 3-ium, 3-(2-
methoxyethyl)-2-methyl-4,9-dioxo-l-(2-pyridylmethyl)-4,9-
dihydro-lH-naphtho[2,3-d]imidazol-3-ium, 3-(2-
methoxyethyl)-2-methyl-4,9-dioxo-l-(4-pyridylmethyl)-4,9-
dihydro-lH-naphtho[2,3-d]imidazol-3-ium, 1-[(2-chloro-3-
pyridyl)methyl]-3-(2-methoxyethyl)-2-methyl-4,9-dioxo-4,9-
dihydro-lH-naphtho[2,3-d]imidazol-3-ium, 1-[(2-hydroxy-4-
21
CA 02395717 2002-06-28
pyridyl)methyl]-3-(2-methoxyethyl)-2-methyl-4,9-dioxo-4,9-
dihydro-lH-naphtho[2,3-d]imidazol-3-ium, 3-(2-
methoxyethyl)-1-[(6-methoxy-3-pyridyl)methyl]-2-methyl-4,9-
dioxo-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium, 1-[(2-
chloro-4-pyridyl)methyl]-3-(2-methoxyethyl)-2-methyl-4,9-
dioxo-4,9-dihydro-lH-naphtho[2,3-d]irnidazol-3-ium, 1-(4-
chlorobenzyl)-3-(2-methoxyethyl)-2-methyl-4,9-dioxo-4,9-
dihydro-lH-naphtho[2,3-d]imidazol-3-ium, 1-(4-
fluorobenzyl)-3-(2-methoxyethyl)-2-methyl-4,9-dioxo-4,9-
dihydro-lH-naphtho[2,3-d]imidazol-3-ium and 1,3-bis(2-
methoxyethyl)-2-methyl-5-nitro-4,9-dioxo-4,9-dihydro-lH-
naphtho[2,3-d]imidazol-3-ium, or tautomers thereof and
their salts with halogen ions.
The compound (I) of the invention exists in tautomer
forms represented by the following formula due to
delocalization of the cation, and these isomers in
separated forms or mixtures thereof are included in the
invention. The compound mentioned herein as 1H-imidazol-3-
ium derivative includes 3H-imidazol-l-ium derivative as its
tautomer and mixture of both isomers. In this connection,
X- does not exist when the compound (I) has a substituent -
COO- and forms intramolecular salt with the imidazolium
cation.
22
CA 02395717 2002-06-28
O R~ 0 R~
1 + I
A N R3 A N R3
R2 X R2 X
(11) O (I") O
In addition to the aforementioned salt with a counter
anion, the compound (I) of the invention forms other salts
in some cases depending on the kinds of substituents, and
these salts are also included in the invention. In
addition, the compound (II) or (III) of the invention also
forms salts in some cases depending on the kinds of
substituents, and these salts are also included in the
invention. Though these salts are not particularly limited
with the proviso that they are pharmaceutically acceptable
salts, acid addition salts with an inorganic acid
(hydrochloric acid, hydrobromic acid, hydroiodic acid,
sulfuric acid, nitric acid, phosphoric acid and the like)
and with an organic acid (formic acid, acetic acid,
propionic acid, oxalic acid, malonic acid, succinic acid,
fumaric acid, maleic acid, lactic acid, malic acid,
tartaric acid, citric acid, methanesulfonic acid,
ethanesulfonic acid, aspartic acid, glutamic acid and the
like) can be cited as illustrative examples of acid
addition salts, and salts with an inorganic base containing
a metal (sodium, potassium, magnesium, calcium, aluminum
and the like) or with an organic base (methylamine,
ethylamine, ethanolamine, lysine, ornithine and the like)
and ammonium salts and the like can be exemplified as salts
with bases.
23
CA 02395717 2002-06-28
Depending on the kinds of substituents, geometrical
isomers and tautomers exist in the compound (I), (II) or
(III) of the invention in some cases, and these isomers in
separated forms or mixture thereof are included in the
invention. Also, since certain compounds of the invention
have asymmetric carbon atom, isomers based on the
asymmetric carbon atom can exist. The invention includes
mixed and separated forms of these optical isomers. Also,
compounds of the invention may sometimes form N-oxide
depending on the kinds of substituents, and these N-oxide
compounds are also included in the invention. In addition,
various hydrates and solvates and polymorphic substances of
the compound (I), (II) or (III) of the invention are also
included in the invention.
(Synthesis methods)
The compounds (I), (II) and (III) of the invention
can be synthesized easily by using similar methods
described in references, e.g., J. Org. Chem. USSR, 1, 1479
- 85 (1965), J. Med. Chem., 7(3), 362 - 364 (1964), JP-A-3-
258765, or by applying the methods known to those skilled
in the art.
in this connection, depending on the kind of
functional group, it may sometimes be effective from the
viewpoint of synthesis techniques to replace the functional
group with an appropriate protecting group, namely a group
which can be easily converted into the functional group, at
24
CA 02395717 2002-06-28
the stage of starting materials or synthetic intermediates.
Thereafter, a desired compound can be obtained by removing
the protecting group as occasion demands. Examples of such
functional groups include a amino group, a hydroxyl group,
a carboxyl group and the like and examples of their
protecting groups include those which are described in
"Protective Groups in Organic Synthesis", 2nd edition,
edited by Greene and Wuts, which may be optionally used
depending on the reaction conditions.
The following describes typical Synthesis methods.
0 0
H
A EXJCNR2 R NH
(IV) 0 O~Rs (VI) O ORs
~ (Synthesis method 1) (Synthesis method 4)
O RI NH2 (V) base
cx? (II) 0R(III) 0
(Synthesis (Synthesis method 3)
method 2) hydrolysis (Synthesis method 5)
H-X R2-X (VII)
0 Ri
i
GIR3
N2 X
(I) 0 R
(In the formula, R' means hydrogen, methoxy or halogen
group, and H-X means an acid which forms anion (preferably
CA 02395717 2002-06-28
hydrogen fluoride, hydrogen chloride, hydrogen bromide,
hydrogen iodide, methanesulfonic acid, ethanesulfonic acid
and the like). The same shall apply hereinafter.)
Synthesis method 1
The compound (II) of the invention can be synthesized
in the usual procedures by allowing a compound (IV) to
react with amines (V). For example, it can be synthesized
by applying the methods described in Chem. Pharm. Bull.,
44(6), 1181 - 1187 (1996), Syn. Comm., 27 (12), 2143 - 2157
(1997), Tetrahedron. Lett., 39(42), 7677 - 7678 (1998) and
the like, and it is advantageous to carry out the reaction
at ambient temperature or under heating in an appropriate
inert solvent (benzene and the like) using reaction
equivalent amounts of the compounds (IV) and (V), or one of
them in an excess amount, if necessary using an appropriate
inorganic base (potassium carbonate and the like) or
organic base (triethylamine and the like) as an acid
capturing agent.
Synthesis method 2
The compound (I) of the invention can be synthesized
in the usual procedures by subjecting the compound (II) of
the invention to cyclization and making it into a
quaternary salt. For example, the reaction can be carried
out by applying the method described in J. Org. Chem. USSR,
1, 1479 - 85 (1965), and it is advantageous to carry out
the reaction at ambient temperature or under heating in an
appropriate inert solvent (e.g., an alcohol solvent) using
26
CA 02395717 2002-06-28
a reaction equivalent amount or an excess amount of an
acid.
Synthesis method 3
0 0
0 d H H
R N'Rd N-Re
E3IR3 A l N~Re + A I I N~Rd
(I) Re X (IIa) 0 0 R3 (IIb) 0 p~ R3
0
(In the formula, Rd and Re are any groups defined in R1 and
R2. The same shall apply hereinafter.)
Two compounds (IIa) and (Iib) of the invention can be
synthesized by hydrolysis of the compound (I) of the
invention in the usual procedures. The obtained compounds
can also be made into synthetic intermediates of desired
compound (I) of the invention by subjecting them to
commonly known substituent-modification reactions.
The hydrolysis reaction can be carried out by
applying the method described in J. Med. Chem., 7(3), 362 -
364 (1964) and the like, and it is advantageous to carry
out the reaction at ambient temperature or under heating in
an appropriate inert solvent (ethanol and the like) using a
reaction equivalent amount or an excess amount of a base.
As the base, lithium hydroxide, sodium hydroxide, potassium
hydroxide, sodium carbonate, potassium carbonate can be
exemplified.
Synthesis method 4
The compound (III) of the invention can be
synthesized in accordance with the method described in J.
27
CA 02395717 2002-06-28
Med. Chem., 39(7), 1447 - 1451 (1996) and the like, by
subjecting a compound (VI) to cyclization reaction in the
presence of a base such as sodium hydroxide and the like.
Synthesis method 5
The compound (I) of the invention can be synthesized
by allowing the compound (III) of the invention to react
with a halide (VII) to make it into a quaternary salt. For
example, the reaction can be carried out in accordance with
the method described in J. Med. Chem., 7(3), 362 - 364
(1964), preferably in an appropriate inert solvent (e.g.,
an alcohol solvent) using reaction equivalent amounts of
the compounds (III) and (VII), or one of them in an excess
amount, at ambient temperature or under heating, preferably
under reflux temperature of the solvent.
Other Synthesis methods
In addition to the above Synthesis methods, compounds
of the invention can also be synthesized by various
commonly known modification methods of substituents. For
example, a compound having a substituent containing
sulfonyl bond can be synthesized from a compound having
sulfide bond or sulfinyl bond by usual oxidation reaction.
A N-oxide derivative of a compound having a N atom-
containing heteroaryl group (e.g., pyridyl group) as a
substituent can be synthesized by usual oxidation reaction.
A compound having a carboxylic acid-containing substituent
can be synthesized from a compound having ester or amide
bond by usual hydrolysis reaction. A compound having an
28
CA 02395717 2002-06-28
aminoalkyl group-containing substituent can be synthesized
from a compound having a halogen-substituted alkyl bond by
usual amination reaction. In case that the compounds (II)
and (III) of the invention are in free forms, they can be
made into salts by usual salt forming reaction as occasion
demands.
Synthesis of material compounds
Some of the material compounds of the compounds of
the invention are novel compounds, and these compounds can
be synthesized easily in a similar manner as known material
compounds or by using methods commonly known to those
skilled in the art. Typical synthesis methods are shown
below.
Synthesis scheme 1
O O
, R'
R
q I I N/R q
2 ~ ~ N~Rs
H (IV) 0 O'~_ R3
(VIII) O
The compound (IV) can be synthesized in accordance
with the method described in J. Org. Chem. USSR, 1, 1479 -
85 (1965) and the like, by a usual acylation reaction in
which a compound (VIII) is allowed to react with a reactive
carboxylic acid derivative such as an acid halide, acid
anhydride and the like.
29
CA 02395717 2002-06-28
Synthesis scheme 2
I(i(px) CN --~' ~ NH
N N 2 (X)
(In the formula, B1 represents pyridine ring which
may have one or more substituents. The same shall apply
hereinafter.)
An aminomethylpyridine derivative (X) can be
synthesized by the reduction of a compound (IX) in
accordance with the method described in German Patent No.
3726993 (1989) and the like.
Synthesis scheme 3
0 0 H
A R, R1 NH2 () N'R1
H
NH e*c H N
(XI) 0 0 R3 (VI) 0 0~\ R3
The compound (VI) can be synthesized by the amination
of a compound (XI) in accordance with the method described
in J. Med. Chem., 39(7), 1447 - 1451 (1996) and the like.
Synthesis scheme 4
0 0
A( I R' R2NH2 (V) I I R'
-~ A
R= N'R 2
0
(XII) 0 (VIII) H
The compound (VIII) can be synthesized by the
amination of a compound (XII) in accordance with the method
CA 02395717 2002-06-28
described in J. Het. Chem., 33(1), 113 - 117 (1996), Syn.
Comm., 27(12), 2143 - 2157 (1997), Tetrahedron. Lett.,
39(42), 7677 - 7678 (1998) and the like.
Synthesis scheme 5
O p
, ,
A I I R NaH ~' R
R. 3 H N,R
(XII) 0 ~N\R2 (IV) p
R
p (XI[I) 0 R
The compound (IV) can be synthesized by the amidation
of the compound (XII). It is advantageous to carry out the
reaction by activating a reaction equivalent amount of a
compound (XIII) using an appropriate inorganic base (NaH
and the like) or organic base (NaOMe and the like) in an
appropriate inert solvent (N,N-dimethylformamide (DMF) and
the like) and then allowing it to react with a reaction
equivalent amount or an excess amount of the compound (XII)
at ambient temperature or under heating.
Isolation and purification of the compounds of the
invention synthesized in the above described manner are
carried out by applying general chemical techniques such as
extraction, concentration, evaporation, crystallization,
filtration, recrystallization, various types of
chromatography and the like.
Each form of isomers can be isolated by usual
procedures making use of physicochemical differences among
isomers. For example, racemic compounds can be converted
31
CA 02395717 2002-06-28
into optically pure isomers by a conventional optical
resolution method [e.g., a method in which they are made
into diastereomer salts with a general optically active
acid (tartaric acid and the like) and then subjected to
optical resolution]. Also, a diastereomer mixture can be
separated by fractional crystallization, chromatography and
the like. In addition, an optically active compound can
also be synthesized by using an appropriate optically
active material.
Industrial Applicability
The compounds (I) and (II) of the invention are
useful as anticancer agents which have excellent cancer
cell growth inhibitory activity, low toxicity and wide
margins of safety. Accordingly, the compounds of the
invention have the inhibitory activity on growth of tumors,
preferably all solid tumors and lymphomas, particularly
skin cancer, bladder cancer, breast cancer, uterine cancer,
ovary cancer, prostate cancer, lung cancer, colon cancer,
pancreas cancer, renal cancer, gastric cancer and the like,
thus they are useful for the treatment thereof.
Particularly, they show excellent anti-tumor activity for
many kinds of tumor types in a cancer cell growth
inhibition test and an in vivo tumor growth inhibition test
using a mouse tumor xenograft model, and the activity is
superior to those of some existing anticancer agents.
Accordingly, they are expected as therapeutic agents for
32
CA 02395717 2002-06-28
tumor types which show resistance against existing
anticancer agents.
Effects of the compounds of the invention were
verified by the following tests.
Test Example 1 Cancer cell growth inhibition test
(Test methods) Cell culture: HeLaS3 cells or A375
cells were cultured in Dulbecco's modified Eagle's medium
(DMEM) (mfd. by GIBCO) supplemented with 10% FCS.
Compound evaluation: Cervix cancer HeLaS3 cells or
melanoma A375 cells were added to a gelatin-coated 96 well
plate (mfd. by IWAKI) and cultured overnight in DMEM. On
the next day, a DMSO solution of test compound was added
thereto with varied concentrations, while fixing final
concentration of DMSO solution to 0.1%. After incubation
for 48 hours, cell growth was evaluated by color reaction
with Alamar Blue (mfd. by Biosource).
(Results) The compounds (I) and (II) of the
invention satisfactorily inhibited growth of cancer cells,
and their IC50 values were 1 pM or less.
In addition, the compounds (I) and (II) of the
invention showed similarly excellent cell growth inhibitory
activities also for other cancer cells (non-small cell lung
cancer (EKVX, HOP-92, NCI-H358, A-549, NCI-H460), breast
cancer (MDA-MB-231, MCF7), prostate cancer (PC-3), pancreas
cancer (MIA PaCa-2), colon cancer (WiDr), renal cancer (A-
498), gastric cancer (MKN28), bladder cancer (UC-14) and
fibrosarcoma (HT-1080)).
33
CA 02395717 2002-06-28
Test Example 2 In vivo tumor growth inhibition test
(Test methods) Melanoma A375 cells (2 x 106 cells)
were grafted subcutaneously into the frank of male Balb/c
nude mice. When the tumor volume reached 50 to 100 mm3,
the test compound was intravenously administered once a day
for 2 weeks. Also, saline was intravenously administered
to a control group. Tumor diameter was periodically
measured with a vernier caliper until the next day of the
final administration. The tumor volume was calculated by
the following calculation formula.
Tumor volume (mm3) = 1/2 x[a shorter diameter (mm) ] 2 x a
longer diameter (mm)
(Results) In this test, the compounds (I) and (II)
of the invention satisfactorily-inhibited tumor growth,
e.g., the compounds of Examples 4, 37, 118, 121, 148, 154,
180 and 182 showed 50% or more inhibition of tumor growth
compared to the control group at a dose of 0.3 or 1 mg/kg.
The compounds of the invention showed similarly
excellent anti-tumor activity also in an animal model
transplanted with other cancer cells (prostate cancer (PC-
3) or non-small cell lung cancer (NCI-H358, A-549 and NCI-
H460) ) .
Test Example 3 Mouse single administration toxicity test
(Test methods) The compounds of the invention were
administered by single intravenous administration to Balb/C
mice, and the presence of mortal case during the
observation period of 2 weeks was evaluated.
34
CA 02395717 2002-06-28
(Results) Mortal case was not found by 3 mg/kg
single administration of each of the compounds of Examples
4, 9, 35, 37, 52, 72, 121, 133, 148, 154, 158, 180, 182,
184, 185, 186, 192 and 197 of the invention. On the other
hand, all of respective 2 cases died by 3 mg/kg single
administration of KP-1 and KP-3 disclosed in a prior
report, IQiim. Pharm. Zh., 32(6), 10 - 11 (1998). Thus, it
was shown that the compounds of the invention have low
toxicity in comparison with the prior reported compounds.
Accordingly, since the compounds (I) and (II) of the
invention showed excellent anti-tumor activities against
many kinds of tumor types with low toxicity, it was shown
that they are useful as anticancer agents having good
therapeutic profiles.
The pharmaceutical composition of the invention can
be prepared by a generally used method using one or two or
more of the compounds represented by the general formula
(I) or (II) and pharmaceutically acceptable carriers (drug
carriers, fillers and the like). Its administration may be
either oral administration by tablets, pills, capsules,
granules, powders, solutions, inhalations and the like, or
parenteral administration by intravenous injection,
intramuscular injection, and the like, suppositories, eye
drops, ophthalmic ointments, percutaneous solutions,
ointments, percutaneous adhesive preparations, transmucosal
solutions, transmucosal adhesive preparations and the like.
CA 02395717 2002-06-28
The solid composition for use in the oral
administration according to the present invention is used
in the form of tablets, powders, granules and the like. In
such a solid composition, one or more active substances are
mixed with at least one inert filler such as lactose,
mannitol, glucose, hydroxypropylcellulose, microcrystalline
cellulose, starch, polyvinyl pyrrolidone, magnesium
aluminate metasilicate and the like. In accordance with
the usual procedures, the composition may contain inert
additives such as lubricants (magnesium stearate and the
like) and disintegrating agents (sodium carboxymethylstarch
and the like) and solubilization assisting agent. If
necessary, tablets or pills may be coated with a sugar or a
gastric or enteric coating agent.
The liquid composition for oral administration
includes pharmaceutically acceptable emulsions, solutions,
suspensions, syrups, elixirs and the like and contains a
generally used inert diluent conventionally employed, e.g.,
purified water or ethanol. In addition to the inert
diluent, this composition may further contain an auxiliary
agent such as a solubilizing agent, a moistening agent, a
suspending agent and the like, as well as sweeteners,
flavors, aromatics and preservatives.
The injections for parenteral administration include
a sterile aqueous or non-aqueous solution, a suspension and
an emulsion. Examples of the aqueous solution include
distilled water for injection and saline. Examples of the
36
CA 02395717 2002-06-28
non-aqueous solvent include propylene glycol, polyethylene
glycol, vegetable (oils olive oil and the like), alcohols
(ethanol and the like), polysorbate 80 (trade name) and the
like. Such a composition may further contain a tonicity
agent, a preservative, a moistening agent, an emulsifier, a
dispersing agent, a stabilizer and a solubilization
assisting agent. These compositions are sterilized, e.g.,
by filtration through a bacteria retaining filter, blending
of a germicide or irradiation. Alternatively, they may be
used by firstly making into sterile solid compositions and
then dissolving or suspending them in sterile water or a
sterile solvent for injection use prior to their use.
In the case of oral administration, suitable daily
dose is usually about 0.001 to 50 mg/kg, preferably about
0.01 to 30 mg/kg, and in the case of intravenous
administration, the daily dose is usually about 0.0001 to
10 mg/kg, preferably about 0.001 to 3 mg/kg, and the daily
dose is divided into 1 to several doses per day. The dose
may be appropriately determined for each case, depending on
conditions, age, sex and the like.
Best Mode for Carrying Out the Invention
The following describes the invention further in
detail based on examples. The compounds of the invention
are not limited to the compounds described in the following
examples. In this connection, Synthesis examples of
37
CA 02395717 2002-06-28
material compounds of the compounds of the invention are
shown in Reference Examples.
Reference Example 1: Saturated aqueous ammonia (17
ml) and Raney nickel (3.0 g) were added to a solution of 3-
cyano-2-(dimethylamino)pyridine (2.45 g) in ethanol (50 ml)
and the mixture was stirred at room temperature for 8 hours
under a hydrogen atmosphere of 1 atmospheric pressure.
After absorption of 760 ml of hydrogen, the catalyst was
removed by filtration. By concentrating the mother liquid,
3-(aminomethyl)-2-(dimethylamino)pyridine (2.61 g) was
obtained as a yellow oil.
Reference Example 2: A few drops of concentrated
sulfuric acid was added to a solution of 2-chloro-3-[(2-
methoxyethyl)amino]-1,4-naphthoquinone (33 g) in acetic
anhydride (100 ml) and the mixture was stirred at 45 C for
1 hour. By adding ethanol (100 ml) to the reaction
solution, excess acetic anhydride was esterified. After
cooling, ethyl acetate was added to the reaction solution
and the mixture was washed with water and brine and then
dried over anhydrous sodium sulfate. The solvent was
evaporated and the residue was crystallized from diethyl
ether to give N-(3-chloro-1,4-dihydro-1,4-dioxo-2-
naphthalenyl)-N-(2-methoxyethyl)acetamide (29 g) as a
yellow powder.
Reference Example 3 2-Methoxyethylamine (0.8 ml) was
added to a solution of N-(3-chloro-1,4-dihydro-1,4-dioxo-2-
naphthalenyl)acetamide (1.0 g) in benzene (20 ml) and the
38
CA 02395717 2002-06-28
mixture was stirred at room temperature for 1 hour. Water
was added to the reaction solution and the mixture was
extracted with chloroform. The organic layer was washed
with water and brine and then dried over anhydrous sodium
sulfate. The solvent was evaporated and the residue was
recrystallized from ethyl acetate to give N-[3-(2-
methoxyethyl)amino-l,4-dihydro-1,4-dioxo-2-
naphthalenyl]acetamide (0.87 g) as a red powder.
Reference Example 4: 2-(Aminomethyl)pyrazine (3.2 g)
and diisopropylethylamine (5.8 ml) were added to a solution
of 2,3-dichloro-1,4-dihydro-1,4-dioxonaphthalene (3.0 g) in
benzene (90 ml) and the mixture was stirred at room
temperature for 8 hours. Water was added to the reaction
solution and the resulting precipitate was removed by
filtration and then the filtrate was extracted with ethyl
acetate. The organic layer was washed with water and brine
and then dried over anhydrous sodium sulfate. The solvent
was evaporated and the residue was purified by silica gel
column chromatography (elution with chloroform) to give 2-
chloro-1,4-dihydro-1,4-dioxo-3-[(2-
pyrazinylmethyl)amino]naphthalene (0.23 g) as a light brown
powder.
Reference Example 5: 2-Chloroacetyl chloride (3.3
ml) was added to a solution of 2-chloro-1,4-dihydro-3-
methylamino-1,4-dioxonaphthalene (2.2 g) in 1,4-dioxane (30
ml) and the mixture was stirred under reflux for 14 hours.
After cooling of the reaction solution, the solvent was
39
CA 02395717 2002-06-28
evaporated. Ethanol was added to the residue and the
resulting precipitate was collected by filtration. The
obtained solid was recrystallized from ethanol to give 2-
chloro-N-(3-chloro-1,4-dihydro-l,4-dioxo-2-naphthalenyl)-N-
methylacetamide (2.6 g) as a yellow powder.
Reference Example 6: NaH (440 mg) was added to a
solution of 2-oxopiperidine (1.0 g) in DMF (20 ml) and the
mixture was stirred at room temperature for 30 minutes.
This solution was added in a single portion to a solution
of 2,3-dichloro-1,4-dihydro-1,4-dioxonaphthalene (6.9 g) in
DMF (150 ml) and the mixture was stirred at room
temperature for 17 hours. The reaction solution was poured
into saturated aqueous ammonia and the resulting
precipitate was removed by filtration and then the filtrate
was extracted with ethyl acetate. The organic layer was
washed with water and brine and then dried over anhydrous
sodium sulfate. The solvent was evaporated and the residue
was purified by silica gel column chromatography (elution
with ethyl acetate-hexane 1:10 solution) to give 2-chloro-
1,4-dihydro-1,4-dioxo-3-(2-oxopiperidino)naphthalene (0.49
g) as a light brown powder.
Reference Example 7: 2-Methoxyethylamine (1.6 ml)
was added to a solution of methyl 4,7-dihydro-4,7-
dioxobenzo[b]thiophene-2-carboxylate (2.4 g) in
tetrahydrofuran (100 ml) and the mixture was stirred at
room temperature for 27 hours. After evaporation of the
solvent, the residue was purified by silica gel column
CA 02395717 2002-06-28
chromatography (elution with chloroform) to give methyl
4,7-dihydro-5-(2-methoxyethyl)amino-4,7-
dioxobenzo[b]thiophene-2-carboxylate (1.5 g) as a yellow
powder.
Reference Example 8: Five drops of concentrated
sulfuric acid was added to a solution of methyl 4,7-
dihydro-5-(2-methoxyethyl)amino-4,7-dioxobenzo[b]thiophene-
2-carboxylate (1.2 g) in acetic anhydride (20 ml) and the
mixture was stirred at room temperature for 1 hour.
Methanol (20 ml) was gradually added to the reaction
solution and then the solvent was evaporated. Water was
added to the residue and the mixture was extracted with
ethyl acetate. The organic layer was washed with water and
brine and then dried over anhydrous sodium sulfate. After
evaporation of the solvent, the residue was purified by
silica gel column chromatography (elution with ethyl
acetate-hexane 1:1 solution) to give methyl 5-[N-acetyl-N-
(2-methoxyethyl)amino]-4,7-dihydro-4,7-
dioxobenzo[b]thiophene-2-carboxylate (0.39 g) as a reddish
brown powder.
The compounds of Reference Examples 9 to 11 shown in
Table 3 were obtained in a similar manner to that described
in Reference Example 1, and the compound of Reference
Example 12 shown in Table 4 in a similar manner to that
described in Reference Example 2, the compounds of
Reference Examples 13 to 15 shown in Table 4 in a similar
manner to that described in Reference Example 3 and the
41
CA 02395717 2002-06-28
compound of Reference Example 16 shown in Table 4 in a
similar manner to that described in Reference Example 5.
Example 1: 2 M Sodium hydroxide aqueous solution
(0.9 ml) was added to a solution of N-[3-(2-
methoxyethyl)amino-l,4-dihydro-l,4-dioxo-2-
naphthalenyl]acetamide (0.5 g) in ethanol (10 ml) and the
mixture was stirred at room temperature for 15 minutes.
Water was added to the reaction solution and the mixture
was extracted with ethyl acetate. The organic layer was
washed with water and brine and then dried over anhydrous
sodium sulfate. The solvent was evaporated and the residue
was collected by filtration and washed with ethanol to give
1-(2-methoxyethyl)-2-methyl-4,9-dihydro-4,9-dioxo-lH-
naphtho[2,3-d]imidazole (0.58 g) as a light orange powder.
Example 2: Benzylamine (0.5 ml) was added to a
solution of N-(3-chloro-1,4-dihydro-1,4-dioxo-2-
naphthalenyl)-N-(2-methoxyethyl)acetamide (0.5 g) in
benzene (15 ml) and the mixture was stirred at room
temperature for 4 hours. Ethyl acetate was added to the
reaction solution and the mixture was washed with water and
brine and then dried over anhydrous magnesium sulfate. The
solvent was evaporated and the residue was crystallized
from ethyl acetate-hexane to give N-(3-benzylamino-1,4-
dihydro-1,4-dioxo-2-naphthalenyl)-N-(2-
methoxyethyl)acetamide (0.51 g) as a red powder.
Example 3: 80% 3-chloroperbenzoic acid (0.6 g) was
added to a solution of N-(2-methoxyethyl)-N-[3-(3-
42
CA 02395717 2002-06-28
pyridylmethyl)amino-l,4-dihydro-l,4-dioxo-2-
naphthalenyl]acetamide (0.95 g) in dichloromethane (20 ml)
and the mixture was stirred at room temperature for 18
hours. Saturated sodium bicarbonate aqueous solution was
added to the reaction solution and the mixture was
extracted with dichloromethane. The organic layer was
washed with water and brine and then dried over anhydrous
sodium sulfate. The solvent was evaporated and the residue
was purified by silica gel column chromatography (elution
with chloroform-methanol-saturated aqueous ammonia 10:1:0.1
solution) to give 3-[((3-[N-acetyl-N-(2-
methoxyethyl)]amino-l,4-dihydro-1,4-dioxo-2-
naphthalenyl}amino)methyl]pyridine 1-oxide (0.84 g) as a
brown amorphous solid.
Example 4: 1 M Sodium hydroxide aqueous solution
(5.0 ml) was added to a solution of 1-(2-methoxyethyl)-2-
methyl-3-(4-pyridylmethyl)-4,9-dihydro-4,9-dioxo-lH-
naphtho[2,3-d]imidazol-3-ium chloride monohydrochloride
(1.1 g) in ethanol (30 ml) and the mixture was stirred at
room temperature for 30 minutes. Water was added to the
reaction solution and the mixture was extracted with ethyl
acetate. The organic layer was washed with water and brine
and then dried over anhydrous magnesium sulfate. The
solvent was evaporated and the residue was purified by
silica gel column chromatography (fraction A: elution with
ethyl acetate-hexane 1:1 solution, fraction B: elution with
ethyl acetate). The fraction A was crystallized from
43
CA 02395717 2002-06-28
diethyl ether to give N-[3-(2-methoxyethyl)amino-l,4-
dihydro-1,4-dioxo-2-naphthalenyl]-N-(4-
pyridylmethyl)acetamide (0.2 g) as a red powder. In this
connection, the fraction B was crystallized from ethyl
acetate to give a yellow powder (0.31 g) which was found to
be the same compound, N-(2-methoxyethyl)-N-[3-(4-
pyridylmethyl)amino-l,4-dihydro-1,4-dioxo-2-
naphthalenyl]acetamide that will be described later in
Example 37.
Example 5: 80% 3-chloroperbenzoic acid (0.78 g) was
added to a solution of N-methyl-N-{3-[2-
(methylsulfinyl)ethyl]amino-l,4-dihydro-1,4-dioxo-2-
naphthalenyl}acetamide (0.52 g) in dichloromethane (10 ml)
and the mixture was stirred at room temperature for 3
hours. Saturated sodium bicarbonate aqueous solution was
added to the reaction solution and the mixture was
extracted with dichloromethane. The organic layer was
washed with water and brine and then dried over anhydrous
sodium sulfate. The solvent was evaporated and the residue
was purified by silica gel column chromatography (elution
with chloroform-methanol 50:1 solution) to give N-methyl-N-
{3-[2-(methylsulfonyl)ethyl]amino-l,4-dihydro-1,4-dioxo-2-
naphthalenyl}acetamide (0.39 g) as an orange amorphous
solid.
Example 6: 4 M hydrogen chloride/ethyl acetate
solution (3 ml) was added to a suspension of N-[3-(2-
Hydroxyethyl)amino-l,4-dihydro-l,4-dioxo-2-naphthalenyl]-N-
44
CA 02395717 2002-06-28
methylacetamide (0.4 g) in ethanol (3 ml) and the mixture
was stirred at 45 C for 1 hour. After cooling, the
resulting precipitate was collected by filtration and
washed with ethyl acetate. The obtained solid was
recrystallized from ethanol-ethyl acetate to give 1-(2-
hydroxyethyl)-2,3-dimethyl-4,9-dihydro-4,9-dioxo-lH-
naphtho[2,3-d]imidazol-3-ium chloride (0.28 g) as a
colorless powder.
Example 7: Benzyl bromide (1.9 ml) was added to a
solution of 1-isopropyl-2-methyl-4,9-dihydro-4,9-dioxo-lH-
naphtho[2,3-d]imidazole (0.8 g) in acetonitrile (20 ml)
and the mixture was stirred under reflux for 6 hours.
After cooling, the resulting precipitate was collected by
filtration and washed with ethyl acetate. The obtained
solid was recrystallized from methanol to give 1-benzyl-3-
isopropyl-2-methyl-4,9-dihydro-4,9-dioxo-lH-naphtho[2,3-
d]i.midazol-3-ium bromide (0.47 g) as a yellow powder.
Example 8: By the similar method of Example 6, 1-
(2-hydroxy-3-pyridyl)methyl-3-(2-methoxyethyl)-2-methyl-
4,9-dihydro-4,9-dioxo-lH-naphtho[2,3-d]imidazol-3-ium
chloride (0.39 g) was obtained as a light brown powder from
N-(2-methoxyethyl)-N-{3-[(2-methoxy-3-pyridyl)methyl]amino-
1,4-dihydro-1,4-dioxo-2-naphthalenyl}acetamide (0.49 g).
Example 9: 4 M Hydrogen chloride/ethyl acetate
solution (10 ml) was added to a solution of N-{3-[(6-
chloro-3-pyridyl)methyl]amino-l,4-dihydro-1,4-dioxo-2-
naphthalenyl}-N-(2-methoxyethyl)acetamide (0.8 g) in
CA 02395717 2002-06-28
ethanol (10 ml) and the mixture was stirred at room
temperature for 1 day. The solvent was evaporated and the
residue was collected by filtration and washed with ethyl
acetate to give 1-[(6-chloro-3-pyridyl)methyl]-3-(2-
methoxyethyl)-2-methyl-4,9-dioxo-4,9-dihydro-lH-
naphtho[2,3-d]imidazol-3-ium chloride (0.82 g) as a light
yellow powder.
Example 10: 2 M Dimethylamine/tetrahydrofuran
solution (3.0 ml) was added to a solution of 2-chloro-N-
[1,4-dihydro-3-(2-methoxyethyl)amino-l,4-dioxo-2-
naphthalenyl]-N-methylacetamide (0.5 g) in tetrahydrofuran
(30 ml) and the mixture was stirred at room temperature for
18 hours. Water was added to the reaction solution and the
mixture was extracted with ethyl acetate. The organic
layer was washed with water and brine and then dried over
anhydrous magnesium sulfate. The solvent was evaporated
and the residue was crystallized from ethanol to give N-
[1,4-dihydro-3-(2-methoxyethyl)amino-l,4-dioxo-2-
naphthalenyl]-N-methyl-2-(dimethylamino)acetamide (0.19 g)
as a brown powder.
Example 11: 2-Methoxyethylamine (0.15 ml) was added
to a solution of methyl 5-[N-acetyl-N-(2-
methoxyethyl)amino]-4,7-dihydro-4,7-dioxobenzo[b]thiophene-
2-carboxylate (0.39 g) in tetrahydrofuran (30 ml) and the
mixture was stirred at room temperature for 6.5 hours. The
solvent was evaporated and the residue was purified by
silica gel column chromatography (elution with hexane-ethyl
46
CA 02395717 2002-06-28
acetate 50:1 solution) to give methyl 5-[N-acetyl-N-(2-
methoxyethyl)amino]-4,7-dihydro-6-(2-methoxyethyl)amino-
4,7-dioxobenzo[b]thiophene-2-carboxylate (0.39 g) as a
reddish purple oil.
Example 12: 4 M Hydrogen chloride/ethyl acetate
solution (2.5 ml) was added to a suspension of 3-([3-(N-
acetyl-N-methyl)amino-l,4-dihydro-l,4-dioxo-2-
naphthalenyl]amino}propionamide (0.32 g) in methanol (30
ml) and the mixture was stirred at room temperature for 16
hours. After cooling, the solvent was evaporated and the
residue was stirred in ethanol with heating. After
cooling, the resulting precipitate was collected by
filtration and washed with ethanol to give 1-(2-
carboxyethyl)-4,9-dihydro-2,3-dimethyl-4,9-dioxo-lH-
naphtho[2,3-d]imidazol-3-ium chloride (0.15 g) as a
colorless powder.
In a similar manner to those described in the above
Examples 1 to 9, the Example compounds described in Tables
6 to 20 were obtained.
Structural formula and physicochemical properties of
the reference example compounds are shown in Tables 3 to 5,
and those of the Example compounds in Tables 6 to 20. In
addition, the compounds having the chemical structures
described in Tables 21 to 27 can be easily synthesized by
almost the same methods described in the above Examples or
the aforementioned processes, or by applying thereto slight
47
CA 02395717 2002-06-28
modifications which are obvious to those skilled in the
art.
Abbreviations in the tables respectively indicate as
follows, Ref: reference example; Ex: Example; Co: compound
number; Sal: salt; Sy: synthesis method (each numeral
indicates the example number, showing that the compound was
synthesized by the same method of this example); -: does
not exist; Dat: physicochemical properties (F: FAB-MS (M)+;
F': FAB-MS (M) -; F+: FAB-MS (M + H) +; F-: FAB-MS (M - H) -;
E: EI-MS (M) +; Nl :'H-Nbgt (DMSO-d6, TMS internal standard)
characteristic peaks 6 ppm}; i-Pr: isopropyl; c-Pr:
cyclopropyl; Ad: 1-adamantyl; Ac: acetyl; Bn: benzyl; Pipe:
piperidino; Morp: morpholino; Py2: 2-pyridyl; Py3: 3-
pyridyl; Py4: 4-pyridyl; Th: 2-thienyl; Fu: 2-furyl; Thf:
2-tetrahydrofuranyl; Pyr: 2-pyrazinyl; 5-MePyr: 5-
methylpyrazin-2-yl; Pym: 4-pyrimidinyl; Qu: 3-quinolyl;
Dio: 4-benzodioxolyl; Im: 4-imidazolyl; Bim: 2-
benzoimidazolyl; and In: 2-indolyl. In this connection,
the numeral before each substituent indicates its
substitution position, e.g., 3,4-Cl means that -Cl is
substituted at the 3- and 4-positions respectively.
48
CA 02395717 2002-06-28
Table 3
Rf B
N 2 (Xa)
Ref B' -Rf Dat Ref B' -Rf Dat
1 Py3 2-NMe2 F+:152 10 4 2-NMe2 F+:152
9 Py3 6-NMe2 F+: 152 1111 Py3 2-OMe E: 138
Table 4
0
8
JJLNR2
0 Rh
(IVa) or (VIa) or (VIIIa)
Ref -R9 -Rh R2 Dat
2 -CI -Ac CH2WMe N1:1.88(3H,s), 2.99(3H,s), 3.3-
3. 4H,m , 7.9-8.2 4H,m
3 NH CH2 Me -Ac -H F+: 289
4 -CI -H -CH2PYr P:299
5 -CI -COCH2CI -Me F: 298
6 -CI -CO CH2 - F+: 290
12 -CI -Ac -CH2PYr F':341
13 -NH-CH2(Py3) -Ac -H F+: 322
14 -NH-CH 4 -Ac -H F+: 322
-NH-CH2(Pyr) -Ac -H F+:323
16 -CI -COCH2OMe -Me F+: 294
Table 5
0
s
Me02C 2
NIR
o 1
h
R (IVb) or (VIIIb)
Ref Rh R2 Dat
7 -H CH Me F+:296
8 -Ac 14CH2WMe F+:338
49
- - ---- - - ----- - --------- -- -----
CA 02395717 2002-06-28
Table 6
0 R~
i
N
/>-Me
N
0 (IIIa)
Ex. -R' Dat Ex. -R' Dat
1 CH 2OMe F+:271 14 -CH2(Py4) F+:304
13 -CH2(Py3) F+:304 15 -CHZ F+:305
Table 7
H R'
N
*N-~\,"OMe
O Ac (IIc)
Ex -F~ Sy Dat
F+: 379
2-H - N1: 1.34(3H,br), 3.06(3H,s), 3.1-3.8(4H,m), 4.5-4.8(2H,m), 7.
2-7.4(5H,m), 7.77(1 H,dt), 7.85(1 H,dt), 7.93(1 H,br), 7.98(1 H,d
), 8.03 1 H,d
16 2-Cl 2 F+:413
17 3-Cl 2 F+:413
F+: 413
18 4-C1 2 N1: 1.39(3H,br), 3.06(3H,s), 3.1-3.4(2H,m), 3.4-3.5(1H,m), 3.
6-3.9(1 H,m), 4.5-4.8(2H,m), 7.27(2H,d), 7.38(2H,d), 7.7-8.1(4
H,m)
19 3,4CI 2 F:447
20 2-0Me 2 F+:409
21 3-OMe 2 F+:409
22 4-0Me 2 F+: 409
23 4-Ph 2 F+: 455
24 2-CN 2 F+: 404
25 3-CN 2 F+:404
26 4-CN 2 F+:404
27 4-SO2NH2 2 F+:458
28 4-CF3 2 F+:447
F+: 397
29 4-F 2 N1: 1.40(3H,br), 3.06(3H,s), 3.1-3.6(3H,m), 3.79(1H,br), 4.5-4.
8 2H,m , 7.1-7.2 2H,m , 7.2-7.5 2H,m , 7.7-8.2 4H,m
30 4-Br 2 F+: 457, 459
31 3-CH2NH2 2 F+: 408
32 4-CH2NH2 2 F:407
33 3-NO2 2 F+: 424
F+: 424
34 4-NO2 2 N1: 1.39(3H,br), 3.07(3H,s), 3.1-3.6(3H,m), 3.6-3.9(1H,m), 4.
6-5.0 2H,m , 7.54 2H,d , 7.7-8.2 5H,m , 8.19 2H,d
CA 02395717 2002-06-28
Table 8
0 H A,NN3Rf
~ I I N OMe
I
0 Ac (IId)
Ex B' -Rf Dat
3 Py3 1-o)dde - F+: 396
2 F+:380
35 Py3 -H N1: 1.40(3H,s), 3.06(3H,s), 3.1-3.8(4H,m), 4.6-4.8(2H,m), 7.34(
1 H,dd , 7.6-8.16H,m , 8.4-8. 2H,m
2 F+:380
36 Py2 -H N1: 1.62(3H,s), 3.06(3H,s), 3.2-3.9(4H,m), 4.5-5.0(4H,m), 7.2-7
.5 2H,m , 7.7-8.2 6H,m , 8.541 H,d
2 F+:380
37 Py4 -H N1: 1.38(1H,br), 3.07(3H,s), 3.1-3.8(4H,m), 4.6-4.8(2H,m), 7.2
6(2H,d), 7.77(1 H,dt), 7.85(1 H,dt), 7.95(1 H,d), 8.01(1 H,d), 8.4
8 2H,d
2 F+: 414
38 Py3 2-Cl N1: 1.49(3H,s), 3.07(3H,s), 3.1-3.4(2H,m), 3.43.6(1 H,m), 3.6-3
.81 H,m , 4.6y4.9 2H,m , 7.3-7. 1 H,m , 7.7-8.2 6H,m
2 F+: 414
39 Py3 6-Cl N1: 1.47(3H,br), 3.07(3H,s), 3.1-3.6(3H,m), 3.6-4.0(1H,m), 4.6-
4. 2H,m , 7.4 1 H,d , 7.6-8.1 6H,m , 8.341 H,d
40 Py3 2-OMe 2 F+: 410
2 F+: 410
41 Py3 6-OMe N1: 1.49(3H,s), 3.07(3H,s), 3.1-3.5(3H,m), 3.6-3.9(4H,m), 4.5-4
8 2H,m , 6.7 1 H,d , 7.5-7.71 H,m , 7.7-8.2 5H,m
42 2-NMe2 2 F+: 423
43 Py3 6-NMe2 2 F+: 423
44 Py3 5-Me 2 F+: 394
45 Py3 6-Me 2 F:393
46 Py3 6-CF3 2 F+: 448
2 F+: 414
47 Py4 2-Cl N1: 1.48(3H,br), 3.09(3H,s), 3.1-3.6(3H,m), 3.6-3.9(1H,m), 4.5-
5. 2H,m , 7.331 H,d , 7.451 H,s , 7."25H,m , 8. 1 H,d
48 2-NMe2 2 F+: 423
49 2-OMe 2 F+: 410
51
CA 02395717 2002-06-28
Table 9
O H
N, RI
Rz
N'
O Ac (IIe)
Ex -R' -R2 Dat
F+: 380
N1: 1.19(3H,s), 3.26(3H,s), 3.47(4H,br),
44CH2hOMe -CH2(Py4) - 4.27(1 H,d), 4.81(1 H,d), 7.10(1 H,br), 7
.35(2H,d), 7.74(1 H,dt), 7.82(1 H,dt), 7.9
2 1 H,d , 7.98 1 H,d , 8.41 2H,d
50 4CH~20Me -(CH2)20Me 2 N1: 1.83(3H,s), 3.0-3.8(14H,m), 6.9-7.1(
1 H,m , 7.7-7.9 2H,m , 7.9-8.1 2H,m
N1: 1.88(3H,s), 3.23(3H,s), 3.3-3.5(4H,
51 -{CHZ)2OMe -Bn 2 m), 4.4-4.7(2H,m), 6.91(1 H,br), 7.1-7.4
(5H,m), 7.6-8.1 4H,m
F+: 380
N 1: 1.87(3H,s), 3.25(3H,s), 3.4-3.6(4H,
52 -(CH2)~OMe -CH2(Py3) 4 m), 4.31(1 H,d), 4.81(1 H,d), 7.08(1 H,br
), 7.23(1 H,dd), 7.6-7.8(2H,m), 7.81(1 H
,t), 7.88(1 H,d), 7.98(1 H,d), 8.37(1 H,d),
8.45 1 H,s
53 -Bn -Bn 2 F+:411
54 -CH -Bn 2 F+: 412
55 -CH -Bn 2 F+: 412
56 CH Ph CH OMe 2 F+: 393
57 -CH2Th CH OMe 2 F+: 387
58 -CH2Fu CH OMe 2 F+:369
F+: 381
59 -CH2Pyr -(CH020Me 2 N1: 1.60(3H,s), 3.07(3H,s), 3.2-3.8(4H,
m), 4.5-5.3(2H,m), 7.5-8.2(5H,m), 8.5-
8.8 3H,m
60 -CH2Qu CH2 2OMe 2 F+: 430
61 CH CH 2OMe 2 F+: 394
62 4CHkTO) CH Me 2 E: 393
63 CH 4 CH Me 2 F+: 394
64 CH 21n -(CH2)2OMe 2 F+: 432
65 -CH2Dio CH 2OMe 2 F+: 423
66 CH 31m CH 2OMe 2 F+: 397
67 CH 21m CH 2OMe 2 F+: 383
68 -CH2Bim CH2 2OMe 2 F+: 419
69 CH 20 CH2 NH2 CH2 2OMe 2 F+: 376
70 -(CH2)5NH2 CH 2OMe 2 F+: 374
71 -(CH2)20(CH2)2- -(CH2)2OMe 2 F+:420
O CH2 NH2
52
CA 02395717 2002-06-28
Table 10
0
H
1N B
\ I I
N Me
i
0 Ac ~IIf~
Ex -B S Dat
-S02Me - F+: 351
F+: 303
72 -OMe 2 N1: 1.83(3H,s), 2.92(3H,s), 3.29(3H,s), 3.43.7(4H,m), 7.11(1H,
br), 7.7-7. 2H,m , 7.9-8.1(2H,m)
73 -OPh 2 N1: 1.83(3H,s), 2.93(3H,s), 3.6-3.9(2H,m), 4.21(2H,t), 6.8-7.1(3
H,m), 7.2-7.5 3H,m , 7.7-7. 2H,m , 7.9$.1 2H,m
74 -OBn 2 N1: 2.89(3H,s), 3.90(2H,t), 4.19(3H,s), 4.45(2H,s), 4.89(2H,t), 7.
1-7. 5H,m , 7.9-8.12H,m , 8.1-8.3 2H,m
F+: 316
75 -NMe2 2 N1: 1.83(3H,s), 2.18(6H,s), 2.4-2.6(2H,m), 2.94(3H,s), 3.2-3.5(2
H,m), 7.141 H,t , 7.7 7. 2H,m , 7.9-8.1 2H,m
F+: 317
76 -OEt 2 N1: 1.10(3H,t), 1.82(3H,s), 2.92(3H,s), 3.3-3.7(6H,m), 7.09(1 H,b
r), 7.7-7. 2H,m , 7.9-8.1 2H,m
F+: 331
77 -OPr 2 N1: 0.85(3H,t), 1.41.6(2H,m), 1.83(3H,s), 2.92(3H,s), 3.37(2H,t)
, 3.43.7 4H,m , 7. 1 H,br , 7.7-7. 2H,m , 7.9-8.1 2H,m
F+: 331
78 -O(i-Pr) 2 N1: 1.07(6H,d), 1.82(3H,s), 2.92(3H,s), 3.4-3.7(5H,m), 7.08(1 H,
br), 7.7-7. 2H,m , 7.9-8.1 2H,m
79 -0 CH2 NH2 2 F+: 332
F+: 413
80 -OCH2(F'y3) 2 N1: 1.79(3H,s), 2.90(3H,s), 3.5-3.8(4H,m), 4.55(2H,s), 7.1
7.3(1
H,m), 7.2-7.5(1 H,m), 7.7-7.9(3H,m), 7.9-8.1(2H,m), 8.4-8.6(2H
,m)
81 -SMe 2 F+: 319
82 -NEt2 2 F+:344
83 -N i-Pr 2 2 F+: 372
84 -Pipe 2 F+:356
85 -Morp 2 F+: 358
F+: 330
86 -NHAc 2 N1: 1.81(6H,s), 2.90(3H,s), 3.2-3.7(4H,m), 7.36(1 H,br), 7.7-8.2(
5H,m)
87 -OCONHPh 2 F+: 408
88 -CONH2 2 F+:316
89 -CN 2 F+: 298
90 -0 CH2 Me 2 F+: 347
53
CA 02395717 2002-06-28
Table 11
0 H
N'R1
\ ijLNR2
Ac
(~ie)
Ex -R' -R2 S Dat
N1: 1.7 2.0(5H,m), 2.92(3H,s), 3.25(3H,s),
91 -(CHz)30Me -Me 2 3.3-3.6(4H,m), 7.2-7.5(1H,m), 7.6-8.2(4H,
m
92 CH Me2 -MB 2 F+: 330
F+: 336
93 -CH2(Py2) -Me 2 N1: 1.5-2.2(3H,m), 2.7-3.0(3H,m), 4.5-5.0(
2H,m), 7.2-7.5(2H,m), 7.6-8.3(6H,m), 8.4-
8.71 H,m
94 -CH -Me 2 F+: 336
95 -CH2 4 -Me 2 F+: 336
96 -CH2CF3 -Me 2 F+: 327
97 -CH2Thf -Me 2 F+: 329
98 - CH2CONH2 -Me 2 F+: 302
99 - CH2CN -Me 2 F+: 284
100 Bn _W 2 F+: 418
101 OCOZEt -Me 2 F':399
102 -Me 2 F+: 357
103 -CH Me Ph CH Me 2 F+: 375
F+: 381
104 -CH2Pym -(CHz)2OMe 2 N1: 1.61(3H,s), 3.08(3H,s), 3.2-3.9(4H,m),
4.6-5.0(2H,m), 7.47.6(1 H,m), 7.7-8.1(5H,
m), 8.7 1 H,d , 9.121 H,d
F+: 381
105 4CH2WMe -CH2PYr 2 N1: 1.88(3H,s), 3.26(3H,s), 3.4-3.9(4H,m),
4.3-5.3(2H,m), 7.6-8.1(5H,m), 8.3-8.6(2H,
m , 8.791 H,d
F+: 395
106 -CH2(5-MePyr) -(CH2)20Me 2 N1: 1.61(3H,s), 2.47(3H,s), 3.07(3H,s), 3.
2-3.8(4H,m), 4.6-5.0(2H,m), 7.7-8.1(5H,m)
, 8.4-8.6 2H,m
54
CA 02395717 2002-06-28
Table 12
Ex -R' -R2 S Dat
F+: 415
107 -CH2Pyr ..CH2Pyr 2 N1: 1.72(3H,s), 4.3-5.3(4H,m), 7.6-8.1(4
H,m), 8.2-8.7(5H,m), 8.69(1 H,s), 8.79(1
H,s)
F+: 414
108 -CH2(Py4) -CH2Pyr 2 NI: 1.58(3H,br), 4.2-5.1(4H,m), 7.29(2H,
d), 7.6-8.1(4H,m), 8.28(1 H,s), 8.3-8.7(4
H,m , 8.7 1 H,d)
109 C17Me CH Me 2 F+: 541
110 -CH2Ad CH2 Me 2 F:437
111 -CH2CHPh2 CH2 ZOMe 2 F: 469
F: 391
112 -(CH2)20(CH2WMe -(CHz,12OMe 2 N1: 1.84(3H,s), 3.0-3.9(18H,m), 6.9-7.2(
1 H,m , 7.7 7.9 2H,m , 7.9-8.1 2H,m
113 {CHZ)O(CH2h0- -{CHz)2OMe 2 F: 435
(CH2)2OMe
114 CH2 4BnO-Ph CH Me 2 F: 515
Table 13
0 H
OMe
A * 2
N~R
0 0 R3 (II9)
Ex A -R2 -R3 Dat
-Me -CH2NMe2 - F+:346
11 MeOZC ~ 1 4CH020Me -Me - F+: 411
115 -Me -CH2CI 2 F+: 337
116 -Me -CH2OMe 2 F+ 333
117 -(CH04- 2 F+: 329
CA 02395717 2002-06-28
Table 14
O
B
Me (Ia)
N
\Me CI -
Ex -B Sal Dat
F-: 270
6 -OH - - NI: 2.90(3H,s), 3.8(2H,br), 4.17(3H,s), 4.74(2H,t), 7.9-8.2(
4H,m)
F: 285
118 -0Me - 6 N1: 2.89(3H,s), 3.25(3H,s), 3.77(2H,t), 4.20(3H,s), 4.8-5.0(
2H,m), 7.9-8.3 4H,m
F-: 346
119 -OPh - 6 N1: 3.01(3H,s), 4.21(3H,s), 4.43(2H,t), 5.13(2H,t), 6.8-7.0(
3H,m), 7.2 7.4 2H,m , 7.9-8.1 2H,m , 8.1-8.3 2H,m
F-: 360
120 -OBn - 6 N1: 2.89(3H,s), 3.90(2H,t), 4.19(3H,s), 4.45(2H,s), 4.89(2H
t , 7.1-7.5 5H,m , 7.9-8.1 2H,m , 8.1-8.3 2H,m
F: 298
121 -NMe2 HCI 6 N1: 2.8-3.0(6H,m), 3.02(3H,s), 3.5-3.8(2H,m), 4.16(3H,s),
5.0-5.2(2H,m), 7.9-8.1(2H,m), 8.1-8.3(2H,m), 11.2-11.5(1
H,br)
F: 299
122 -OEt - 6 N1: 1.06(3H,t), 2.89(3H,s), 3.44(2H,q), 3.80(2H,t), 4.20(3H
s , 4. 2H,t , 7.9-8.1 2H,m , 8.1-8. 2H,m
F: 313
123 -OPr - 6 N1: 0.80(3H,t), 1.3-1.6(2H,m), 2.90(3H,s), 3.35(2H,t), 3.80(
2H,t), 4.20(3H,s), 4.87(2H,t), 7.9-8.1(2H,m), 8.1-8.3(2H,m
F: 313
124 -O(i-Pr) - 6 N1: 1.02(6H,d), 2.89(3H,s), 3.4-3.7(1H,m), 3.79(2H,t), 4.21
(3H,s), 4. 2H,t , 7.9-8.1 2H,m , 8.1-8.3 2H,m
125 CHZ NH2 HCI 6 F: 314
F: 362
126 -OCH2(Py3) HCI 6 N1: 2.90(3H,s), 3.98(2H,t), 4.21(3H,s), 4.68(2H,s),
4.95(2H
t , 7.8-8.1 3H,m , 8.1-8.4 3H,m , 8.6-8.9 2H,m
127 -SMe - 6 F: 301
128 -SO2Me - 6 F: 333
129 -NEt2 HCI 6 E: 326
130 -N i-Pr HCI 6 E: 354
131 -Pipe HCI 6 E: 338
132 -Mo HCI 6 E: 340
56
-- - -----------
CA 02395717 2002-06-28
Table 15
0 R
r
c N * O}- Me (Ib)
N\ Me Ci
0
Ex -R' Sal Dat
F: 312
133 -(CH2)2NHAc - 6 N1: 1.76(3H,s), 2.86(3H,s), 3.4-3.7(2H,m),
4.18(3H,s), 4.69(2H,t), 7.9-8.1(2H,m), 8.
1-8.3 2H,m , 8. 1 H,t
134 CH2 ONHPh - 6 F: 390
F: 299
135 4CHZ)3OMe - 6 N1: 2.0-2.2(2H,m), 2.88(3H,s), 3.24(3H,s),
3.42(2H,t), 4.18(3H,s), 4.69(2H,t), 7.9-8.1(
2H,m), 8.1-8.3 2H,m
136 CH NMe2 HCI 6 F: 312
F: 318
137 -CH2(Py2) HCI 6 N1: 2.96(3H,s), 4.25(3H,s), 6.14(2H,s), 7.
3-7.6(1H,m), 7.72(1H,d), 7.8-8.3(5H,m),
8.531 H,d
138 -CH2(Py3) HCI 6 F: 318
139 -CH2(Py4) HCI 6 F:318
140 -CH2CF3 - 6 F: 309
141 CH ONH2 - 6 F:298
142 CH CN - 6 F: 280
143 CH O CH2 Me - 6 F: 329
144 -CH2Thf - 6 F:311
145 -CH2CONH2 - 6 F: 284
146 -CH2CN - 6 F:266
57
CA 02395717 2002-06-28
Table 16
0 R
/ I
Me (Ic)
N~ 2 X-
0 R
Ex -R' -RZ X Sal Dat
F: 345
7 -Bn +Pr Br - NI: 1.67(6H,d), 2.95(3H,s), 5.44(1 H,br),
6.01(2H,s), 7.3-7.5(5H,m), 7.9-8.3(4H,
m
F-: 346
147 -Bn 4CHz)20H CI - 6 N1: 2.88(3H,s), 3.86(2H,t), 4.75(2H,t), 6.
02 2H,s , 7.3-7.5 5H,m , 7.9-8.3 4H,m
F-: 328
148 -{CH2)20Me -(CHZ)2OMe CI - 6 N1: 2.89(3H,s), 3.24(6H,s), 3.78(4H,t), 4
.87 4H,t , 7.9-8.1 2H,m , 8.1-8.3 2H,m
149 -CH2(Py4) -Bn CI HCI 6 F: 394
150 -CH2 -Bn CI HCI 6 F: 394
151 CH 2Ph CHZ Me CI - 6 F: 375
152 -CH2Th C 20Me CI - 6 F: 367
153 -CH2Fu CH 2OMe CI - 6 F: 351
F: 363
N1: 2.8-3.2(6H,m), 3.84(2H,t), 4.92(2H,t)
154 -CH2Pyr -(CHZ)2OMe CI - 6 , 6.19(2H,s), 7.8-8.0(2H,m), 8.0-8.2(2
H,m), 8.52(1 H,dd), 8.62(1 H,d), 8.92(1
H,d)
155 -CH2Qu CH2 Me CI HCI 6 F: 412
156 CH2 CH CI HCI 6 F: 376
157 CH C 20Me CI HCI 6 F: 376
158 CH 4 CH 2OMe CI HCI 6 F: 376
159 CH 2In CH 2OMe CI - 6 F: 414
160 -CH2Dio CH2 OMe CI - 6 F: 405
F: 379
N1: 2.3-2.6(2H,m), 2.98(3H,s), 3.27(3H,
161 -{CH2)3Im -(CH2)2OMe CI HCI 6 s), 3.79(2H,t), 4.45(2H,t), 4.76(2H,t), 4.
86(2H,t), 7.73(1 H,d), 7.95(1 H,d), 7.9-8.
1(2H,m), 8.1-8.3(2H,m), 9.40(1 H,s), 15
.14 1H,br
F: 365
N1: 2.71(3H,s), 3.26(3H,s), 3.34(2H,t), 3
162 -(CH2)21m 4CHkOMe CI HCI 6 .79(2H,t), 4.81(2H,t), 5.00(2H,t), 7.50(1
H,s), 7.9-8.1(2H,m), 8.1-8.3(2H,m), 9.0
4 1 H,s , 14.76 1 H,br , 15.49 1 H,br
163 -CH2Bim CH 2OMe CI HCI 6 F: 401
58
CA 02395717 2002-06-28
Table 17
O R~
C Me (Ic)
C~-
N\ 2 X-
O R
Ex -R1 -RZ X al Dat
12 CHZ 2C02H -Me CI - - F+: 299
164 N~2)~(C~~ -(CH2)2OMe CI HCI 6 F: 358
165 CH2 5NH2 CH2 2OMe CI HCI 6 F: 356
166 4CH2)2qCH2)--- 4CH2)2OMe Cl HCI 6 F: 402
O CH NH2
167 -CH Me Ph CH2 2OMe Cl - 6 F: 375
F: 377
N1: 2.99(3H,s), 3.27(3H,s), 3.82(2
168 -CH2(5-MePyr) 4CHz)2OMe Cl - 6 H,t), 4.92(2H,t), 6.13(2H,s), 7.9-8
.1(2H,m), 8.1-8.3(2H,m), 8.4-8.5(
1 H,m , 8.7-8.9 1 H,m
F: 397
169 -CH2Pyr -CH2Pyr CI - 6 N1: 3.09(3H,br), 6.24(4H,br), 7.7-
8.3(4H,m), 8.5-8.8(4H,m), 9.00(2
H,d)
F: 396
N1: 2.96(3H,s), 6.11(2H,s), 6.20(2
170 -CH2(Py4) -CH2Pyr Cl - 6 H,s), 7.3-7.5(2H,m), 7.8-8.1(2H,
m), 8.0-8.2(2H,m), 8.5-8.8(4H,m)
9.01 1 H,d)
171 -Me CI HCI 6 F: 400
172 ~NCOZEt 4vie CI - 6 F: 382
173 -Me CI - 6 F: 339
174 CH 17Me CH Me CI - 6 F: 523
175 -CH2Ad CH Me CI - 6 F: 421
176 -CH2CHPh2 CH Me Cl - 6 F: 451
F: 373
-(CH2)20(CH2h- N1: 2.91(3H,s), 3.15(3H,s), 3.24(3H,s)
177 OMe 4CH2)20Me CI - 6 3.3-3.4(2H,m), 3.4-3.6(2H,m), 3.79(
2H,t), 3.87(2H,t), 4.7-5.0(4H,m), 7.9-
8.1 2H,m , 8.1-8. 2H,m
178 {CHz)20(CH2)2- 4CH2)zOMe CI - 6 F: 417
O CH2 Me
179 4CH2)20(~ 4CHz)2OMe Cl - 6 F: 497
BnO-Ph)
59
CA 02395717 2002-06-28
Table 18
0 B 1 Rf
+Me _
N Cl (Id)
0 _.QMe
1
Ex B' -Rf Sal Dat
8 Py3 2-OH - - F: 378
F: 396
9Py3 6-Cl - - N1: 2.91(3H,s), 3.25(3H,s), 3.79(2H,t), 4.86(2H,t), 6.05
(2H,s), 7.59(1 H,d), 7.87(1 H,dd), 7.9-8.1(2H,m), 8.1-8.
3 2H,m , 8.45 1 H,d
F: 362
180 Py3 H HCI 6 N1: 2.93(3H,s), 3.26(3H,s), 3.80(2H,t), 4.88(2H,t), 6.16
2H,s , 7.8-8.3 6H,m , 8.7-8.9 2H,m
F: 362
181 Py2 H HCI 6 N1: 2.98(3H,s), 3.28(3H,s), 3.84(2H,t), 4.93(2H,t), 6.17
(2H,s), 7.3-7.6(1 H,m), 7.71(1 H,d), 7.8-8.4(5H,m), 8.52
1 H,d
F: 362
182 Py4 H HCI 6 N1: 2.92(3H,s), 3.28(3H,s), 3.83(2H,t), 4.92(2H,t), 6.35
(2H,s), 7.9-8.3 6H,m , 8.98 2H,d
183 1-odde HCI 6 F: 378
F: 396
184 Py3 2-Cl HCI 6 N1: 2.92(3H,s), 3.28(3H,s), 3.84(2H,t), 4.93(2H,t), 6.03
(2H,s), 7.3-7.6(2H,m), 7.9-8.0(2H,m), 8.0-8.3(2H,m), 8
.42 1 H,dd
F: 378
185 Py4 2-OH _ 8 N1: 2.84(3H,s), 3.26(3H,s), 3.81(2H,t), 4.88(2H,t), 5.84
(2H,s), 5.96(1 H,s) ,6.22(1 H,dd), 7.44(1 H,d), 7.9-8.1(2
H,m), 8.1-8.3 2H,m
F: 392
186 Py3 6-OMe HCI 6 NI: 2.92(3H,s), 3.24(3H,s), 3.7-4.0(5H,m), 4.6-5.5(2H,
m), 5.97(2H,s), 6.87(1 H,d), 7.75(1 H,d), 7.9-8.1(2H,m),
8.1-8.4 3H,m
187 2-NNIe2 HCI 6 F: 405
188 Py3 6-NMe2 HCI 6 F: 405
189 Py3 5-Me HCI 6 F: 376
190 Py3 6-Me HCI 6 F: 376
191 Py3 6-CF3 HCI 6 F: 430
F: 396
192 Py4 2-Cl HCI 6 N1: 2.87(3H,s), 3.27(3H,s), 3.81(2H,t), 4.90(2H,t), 6.09
2H,s , 7.3-7.5 3H,m , 7.8-8.4 4H,m , 8.45 1 H,d
193 4 2-NMe2 HCI 6 F: 405
CA 02395717 2002-06-28
Table 19
~;
0 r-O
~ + -- Me _
~ CI (le)
N, f~Me
0
/
Ex 0, Sal Dat
F: 361
194 H - 6 N1: 2.85(3H,s), 3.24(3H,s), 3.80(2H,t), 4.88(2H,t), 6.05(3H,
s), 7.27. 5H,m, 7.9-8.34H,m
195 2-Cl - 6 F: 395
196 3-Cl - 6 F: 395
F: 395
197 4-Cl - 6 N1: 2.85(3H,s), 3.24(3H,s), 3.79(2H,t), 4.86(2H,t), 6.02(2H,
s), 7.34 2H,d , 7. 2H,d , 7.9-8.1 2H,m , 8.1-8.3 2H,m
198 3,4-Cl - 6 F+:431
199 2-OMe - 6 F: 391
200 3-OMe - 6 F: 391
201 4-OMe - 6 F: 391
202 4-Ph - 6 F: 437
203 3-CN - 6 F: 386
204 4CN - 6 F: 386
205 4-SO2NH2 - 6 F: 440
206 4-CF3 - 6 F: 429
F: 379
207 4-F - 6 N1: 2.87(3H,s), 3.24(3H,s), 3.79(2H,t), 4.87(2H,t), 6.03(2H,
s), 7.1-7.6 4H,m , 7.9-5.1 2H,m , 8.1-8.3 2H,m
208 4-Br - 6 F: 439, 441
209 3-CH2NH2 HCI 6 F: 390
210 4-CH2NH2 HCI 6 F: 390
211 3-NO2 - 6 F: 406
F: 406
212 4-NO2 - 6 N1: 2.87(3H,s), 3.26(3H,s), 3.81(2H,t), 4.89(2H,t), 6.18(2H,
s), 7.61(2H,d), 7.9-8.4(6H,m)
61
CA 02395717 2002-06-28
Table 20
0
OMe
)
cxiii+ N R CI - (If
\ 2
0 R
Ex A -R2 -R3 I JS~ Dat
213 -Me -CH2OMe - 6 F: 315
214 -Me -CH2NMe2 HCI 6 F: 328
~
215 6 F: 311
p F: 374
216 -(CH~OMe -Me - 6 N1: 2.90(3H,s), 3.72(2Ht), 3.77
(2H,t), 4.81(2H,t), 4.87(2H,t), 8
NO2 .1-8.5(3H,m)
217 -(CH2)2OMe -Me HCI 6 F: 330
N
s
218 MeOZC ~ ~ 4CH2)2OMe -Me - 6 F: 393
62
CA 02395717 2002-06-28
Table 21
0 R~
~ ~*J~ R3 (Ig)
$ R2 CI-,
0
Co R' R2 R3 11 Co R' R2 R3
-CH2CH=CH- -(CH2hN(Me) -
1 CH2OMe -(CH~N(Bnh Me 18 -(CH2)20Me COPh Me
2 CH2 2OMe -CH Ph O2Et Me 19 Me CH2 2NO2 Me
3 CH2 2OMe CH OZNH2 Me 20 CH2 Me CH2 2CN Me
4 Me CH HzPh Me 21 CH Me -CH2COPh Me
5 CH2 2OMe CH2 O2H Me 22 CH Me -CH2CONH2 Me
6 CH2 2OMe CH CO Me 23 CH Me CH2 Ac Me
7 CH2 20Me CH 2CONH2 Me 24 Me CH2 Me
8 4CH2hOMe N[(CHkNMe2h Me 25 ~CH ~NH NCMe Bn Me
9 -(CH02OMe 4CHO(CH2)2- Me 26 -(CHZ)2OMe -(CH2)2- Me
NH CH2 NMe2 NHSO2Me
-{CHZ)2OMe 4CH2W(Py4) Me 27 {CHkOMe {CH2)r CONHOMe w
11 ~H2C-C- {CH~-
Me
CH2OMe NHCONH2 Me 28 4CHkOW {CHZ)2OC0-
CH2CO2Et
12 CH2 2OMe CH2 O2Me Me 29 Me CH OMe Me
13 CH2 20Me Me CF3 30 CH Me Me o-Pr
14 -CH2(Pyr) 4CHkOMe H 31 Me -(CHkOMe 4CH2)r
OMe
-{CHkOMe 4C H N Me 32 4CHkOMe {CH NMe2 Me
16 ~CHk0- 4CH~OMe Me 33 {CH~ -(CH2)2OMe Me
o-Pr (CH2VMOrP)
17 CH Me CH Hz- 34 CH2 Me CH2 N Me Hr
5 Table 22
O R~
5
6
7 + R3 (Ih)
Ra a i CI-
O Me
Co R~ R3 R4 Co R' R3 R4
35 I -CH2 4 Me 7-CF3 0 37 I -CH2 H 6-NMe2
36 -CHZ 3 Me 5-CH2NH2 1138 CHZ 2OMe Me 5-NO2
63
CA 02395717 2002-06-28
Table 23
O /-1
s / OMe
~ CR3
7
Ra $ N2 CI
O R
Co R2 R3 R4 Co R2 R3 R4
39 -CH2 Me 5-F 57 -CH2(Py4) i-Pr 5-OMe
40 -CH2 4 Me 6-F 58 -CH2(Py3) Me 6-OMe
41 CH2 2OMe Me 7-F 59 -C Me 7-0Me
42 -CH2 H 8-F 60 CH2 Me Me 8-0Me
43 -CH2 Me 8-CN 61 -CH2(Py4) Me 5-CN
44 -CH2 Me 5-CF3 62 -CH2(Py3) Et 6-CN
45 CH Me Et 6-CF3 63 CHz 2OMe Me 7-CN
46 CHZ 2OMe Me 5,8-OH 64 -CH Me 8-CF3
47 -CH Me 8-CH2NH2 65 CH Me Me 5-CH2N Me Bn
48 -CH2(Py4) Me 7-Me 66 CH Me H 6-CH2NH2
49 -CH2 Me 8-Me 67 -CHZ Me 7-CH2NH2
50 CH Me Me 7-NMe2 68 -CH Me 6-Me,7-F
51 -C Me 8-NMe2 69 -CH2(Py3) Me 5-NMe2
52 -CH2 Me 6,7-diMe 70 CH Me Me 5,8-OMe
53 -CH2 4 H 6-NO2 71 CH Me Me 5-CH2N Me OPh
54 CH OMe Me 5-Me 72 -CHz Me 7-NO2
55 -CH i-Pr 6-Me 73 -CH2(Pyr) Me 8-NO2
56 CHZ Me 5-CH2NMe2 74 CH Me Me 5-CH2
5 Table 24
0 R
5 i
Me
7 ~ C~',
8 R2 X-
0
0
Co R' R2 X Co R~ R2 X
75 -CH2 CH 2OMe Br 81 -CH2(Pyr) CH2 02"
76 -CH2(Py3) CH 2OMe Br 82 -CH CH 02
77 -CH2 CH2 2OMe AcO 83 -CH2(Py3) -CH2CO2
78 -CH2(Pyr) CH2 2OMe AcO 84 CH Me -CH2COj
-
79 -CH2 (Py 3 CH2 Me PhSO3 85 -C CH2 Me I
80 CH2 Me CH2 ZOMe PhSO3 86 CH Me CH OMe I
64
CA 02395717 2002-06-28
Table 25
0 R1
1if51>_Me (1k)
8 N2 Cf
0 R
Co R' R2 Co R' R2
87 -(CH22OMe CHZCO / \ 1 ~ -CHZCO / ~ 4CH2)2OMe
CO2Et CONMe2
88 4C, ~h-~~ -(CHZ)2OMe 105 -CH2 / \ sMe 4CHz)2OMe
8
89 ~CH2)~OMe ccHa)- ~~-cN 106 -(CH2)2OMe -cHz~-Ci
2- ( C'
90 4CH2)2OMe -w
107 Me (cH2)2--&NMe2
N
91 -(CH2)2OMe -(CH2)2 C-NMe2 108 -{CH2)2OMe -(CHZ)Zo-co
92 -(CHZWMe -cH~ (/ NN 109 -(CH~OMe ~H2-C~NDI
N
93 -(CH*OMe cH2 /\ oMe 110 -(CH020Me cH2--CN
94 -CH2S "'~ -(CH~OMe 111 -cH2--( ~-A~ Me
95 -(CH02OMe -cH2: N 112 -(CH~OMe -CHZ ~ \ oAc
N
96 4CH*OMe -(CH2)Z~-Me 113 -{CH~CMe -CH2 NHAc
N
97 -(CH2)20Me -(cHZ)Z-~-NMe2 114 -(CH02OMe cH2--C'
N
98 Me -(CHZ)Z N~NMe 115 -(CH2)20Me -CH2--(~ NN
99 4CH2WMe CHZ 1N~ 116 -CH2 NS j 4CH2)zUMe
100 -CH2NMe 4CH2)20Me 117 Me -cH2N, N
N-NH
101 -(CH2)2OMe -cHz /\cl 118 -(CH~OMe -CHz--(N \ cl
N=N N
102 4CH~OMe -cH2 N=N 119 -cH--~N cl -(CH2)2OMe
103 Me ~HZ ~S~N 11 120 -cHZ--<N~ -{CH2)20Me
CA 02395717 2002-06-28
Table 26
Co R' R2 Co R' R2
121 oH2 N~o -(CH2)zOMe 126 -(CH~OMe -cH2-~N~
122 4CH2)2OMe -CHZ \o,N 127 -(CH2~OMe -CHZ N~ wie
0
0
123 4CH2hOMe ~HsaCHz~sN I ~ 128 -(CH22OMe CH2OCHz-~0
0
124 4CHZ)2OMe -CH20CH2 &ol 129 -(CH2)2OMe -CH20~Hi-Q
Meo
125 4CHW20Me -cH2S 130 c"zs \ " 4CH2)2OMe
Table 27
O R
i
A + Me (Im)
N CI-
O R
Co R' RZ A Co R' R2 A
131 4CH2)~OMe -(CH~OMe <ox 138 -(CH020Me -(CHkOMe ~N
132 4CHZ
)2OMe 4CH2)20Me Csx 139 -(CHkOMe -{CH2)2OMe ~Nx
133 -CH2(Py3) 4CH~OMe ~H~l 140 -(CHkOMe -CH2(Pyr) C
Nx
N;~
134 -(CHkOMe -(CH~J2OMe ~~=1 141 -(CH2)2OMe -(CH2)2OMe N aj
135 -CHX~) -(CHZ)2OMe N 142 -CH2(Py4) 4CFiZ)2OMe N N~
136 4CH2)2OMe {CH2)2OMe ~ I 143 -(CH02OMe 4CH2hOMe o N I
137 -(CH~OMe {CH2)2OMe ~ 1 144 4CH2hOMe -CH2(Py4) Cx
66
